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PREFACE
Source of Hypochlorous Acid in biological system
In humans, hypochlorous acid (HOCl) is generated by the enzyme myeloperoxidase
(MPO) using hydrogen peroxide (H2O2) and chloride (Cl-) as substrates [1]. Structurally, MPO
is a highly cationic, glycosylated, heterodimeric heme protein with a mass of 146 Kd [2]. Under
normal conditions, MPO is stored in an inactive form in the azurophilic granules of the
neutrophil. Following neutrophil activation, the azurophilic granules are secreted out from the
cell leading to release of active MPO. Concurrent to the release of MPO, membrane bound
NADPH oxidase (NOX) is also activated [1]. Activation of NOX leads to the generation of
superoxide, which then either spontaneously or enzymatically (through the action of super oxide
dismutase) dismutates to form H2O2. MPO uses the NOX generated H2O2 as an electron donor to
catalyze the oxidation of Cl- to HOCl [1].
Crystal structure of the MPO active site revealed that it contains a non-planar porphyrin
ring which is covalently attached to the protein via two ester bonds Asp94 and Glu242 and one
sulfonium linkage Met243 (see Figure 1) [3-4]. The redox properties of the heme iron, which
plays a pivotal role in the catalytic mechanism of the enzyme, are significantly affected by these

Figure 1: MPO heme structure.(modified from [4]).
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modifications [3]. Detailed characterization of the MPO catalytic cycle showed that the heme
iron cycles between ferric and its higher oxidation state, ferryl forms. The secreted form of the
enzyme has the heme iron in ferric state and is denoted as MPO-Fe(III). MPO-Fe(III) interacts
with H2O2 and is converted to Compound I (MPO-Fe(IV)=O+

π●

), a ferry porphyrin π cation

radical. There are two pathways by which Compound I could be converted back to MPO-Fe(III),
the halogenation cycle or the peroxidase cycle. In the halogenation cycle, Compound I in the
presence of Cl- is converted back to MPO-Fe(III) by a one step 2 electron oxidation pathway
generating HOCl. Alternatively, Compound I can utilize various organic substrates (such as
tyrosine, ascorbate and urate) through a two-step one electron oxidation pathway and is
converted to MPO-Fe(III) (reviewed in [1]). Figure 2 shows a schematic representation of the
MPO catalytic cycle.

Figure 2: MPO catalytic cycle.
Although HOCl is known to play a beneficial role in the host defense mechanism, HOCl
mediated damage is not limited to the intraphagosomal microbes.

HOCl is incapable of

differentiating between foreign and host tissue. On the basis of in vitro studies using isolated
human neutrophils, it has been estimated that at sites of inflammation activated neutrophils can
generate millimolar levels of HOCl [5, 6].

This sustained high level of HOCl can cause

significant host tissue damage and has been implicated to play a role in a number of pathological
conditions.
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HOCl and its biological targets
HOCl is known to react with a wide array of biomolecules ranging from amino acids,
proteins, nucleic acid and lipids, and can oxidatively modify them. Nucleophiles, especially
those containing sulfur or nitrogen atoms such as thiols, thioethers, amines and amides are most
susceptible to HOCl mediated oxidation [7-9]. The modifications of the amine group of amino
acids by HOCl lead to the formation of chloramines [1, 10-12]. Chloramines such as taurine
chloramines are toxic and are capable of inflicting cellular damage by different pathways [1316].

Chloramine formation has also been observed in free nucleobases, nucleosides, and

nucleotides, as well as in DNA and RNA [17-19]. For example, NADH and NH-groups of
pyrimidine nucleotides are chlorinated by a HOCl-induced reaction [20].

HOCl mediated

oxidation has been known to cause extensive denaturation of double-stranded DNA [16, 17].
HOCl is reactive towards aromatic rings (such as in Tyr and Trp) [10, 21, 22]. Reaction with
Tyr leads to the formation of 3-chlorotyrosine and 3, 5-dichloro tyrosine, both of which are
currently the only known specific biomarkers of HOCl induced damage [10, 23-26]. Reaction of
HOCl with unsaturated fatty acids lead to the addition of a Cl and OH groups across the carboncarbon double bond forming chlorohydrins (RCH=CHR + HOCl-----> RCH(Cl)-CH(OH)R’)
[27-31]. HOCl can cause cell lysis by generating chlorohydrins in the membrane phospholipids
[32-34].
In addition to being a potent oxidant itself, HOCl can react with other compounds to
produce other reactive oxidant species (ROS). For example, HOCl can react with O2- to
generate hydroxyl radical (OH) [35, 36]. In alkaline solution hypochlorite (OCl-), the conjugate
base of HOCl reacts with H2O2 to yield singlet oxygen species [37]. Importantly, these ROS and
free radicals, subsequently generated from HOCl may cause further cellular damage.
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Through these mechanisms, excessive HOCl production can cause significant host tissue
damage. Indeed, HOCl is implicated as a contributing factor in a number of pathological
conditions including inflammatory diseases, atherosclerosis, respiratory distress, acute vasculitis,
rheumatoid arthritis, glomerulonephritis and cancer [11-15].
Involvement of HOCl in human pathological conditions
Increasing evidence points to the fact that HOCl mediated damage plays an important
role in the initiation and progression of a number of pathological conditions, especially those
having a major inflammatory component [1]. Evidence for the role of HOCl in these diseases
comes from the fact that both active MPO (the source of HOCl) and specific biomarkers of
HOCl mediated damage (3-chloro tyrosine) are found in the diseased tissues [1]. In fact the most
comprehensive and compelling evidences for the involvement of HOCl is found in cardiac
diseases [1]. Enzymatically active MPO has been found in all stages of human atherosclerotic
lesions [38] as evident by the marked increased in the level of 3-chlorotyrosine in atherosclerotic
lesions as compared to healthy tissue [25].

Involvement of HOCl is not only limited to

cardiovascular diseases but it is also associated with cancer. HOCl chlorinated DNA bases are
effective mutagens, clastogen and induce sister chromatid exchange [39].

Additionally an

elevated expression of MPO has been observed in the brains of the patients with
neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease and multiple
sclerosis [40-43].
Heme destruction as a possible pathway for generation of free iron
The evidence for the role of HOCl in mediating heme destruction and generation of free
iron comes from the fact that in several pathological conditions such as atherosclerosis and sickle
cell disease, there is significant free iron accumulation. For example, in atherosclerosis, a
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condition where the role of HOCl is well documented, there are reports of prominent iron
deposition in the atherosclerotic lesions [44].

The source of this iron is thought to be

Hemoglobin (Hb) that is released from ruptured red blood cells (RBC) at the sites of
hemorrhagic atheromatous plaques [45, 46]. Moreover it is also well known, that in sickle cell
disease there is an increased iron accumulation [47]. A study by Mohamed et. al. has shown that
sickle cell patients have an increased in-vivo activation of neutrophils and show significantly
increased levels of plasma MPO levels compared to healthy controls [48].

The plasma

concentration of MPO showed a significant inverse correlation with the Hb concentration [48].
Although, these studies do suggest interplay between HOCl and Hb in generating free iron, the
exact mechanism of the process has not been elucidated.
Reactive oxygen species mediated heme degradation
Heme degradation in humans can occur either enzymatically by the heme oxygenase
(HO) enzyme system or non-enzymatically by the action of ROS, reducing agents, or xenobiotics
(as reviewed in [49]). In contrast to the enzymatic pathways (which targets only α carbon
methene bridge), ROS mediated heme degradation occurs in a relatively random fashion
whereby any of the carbon-methene bridges in the tetrapyrrole ring could be cleaved, forming
various pyrrole products and thus releasing iron [49]. Several non-ezymatic heme degradation
products have been characterized using NMR and mass spectrometric studies (reviewed in [49]).
Nagababu and Rifkind have shown that the reaction of heme and hemin with H2O2 produces
fluorescent heme degradation products [50]. Additionally, the heme moiety of hemoproteins
such as cytochrome C and Hb are also susceptible to ROS mediated degradation. H2O2 has also
been reported to react with hemoproteins like Hb and cytochrome C to generate similar
fluorescent heme degradation products, and cause free iron release [50-52]. A recent study from
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our laboratory has shown that peroxynitrite with H2O2 in the presence of low Cl- can cause heme
depletion from MPO [53]. These findings clearly indicate that ROS can interact with free heme
and hemoproteins to cause heme degradation and release catalytically active free iron. We
hypothesized that HOCl, a potent oxidant, can degrade free heme and as well as the heme moiety
in Hb to release free iron.
HOCl mediated depletion of free heme and destruction of Hb could have a potential toxic
outcome by disrupting the oxygen carrying function of Hb, destabilizing the cellular heme
homeostasis and accumulation of toxic free iron.
Consequences of hemoglobin destruction
Destruction of the heme moiety of Hb will render it functionless since it cannot bind
oxygen and perform its normal physiologic function of transporting oxygen from the oxygen-rich
atmosphere of the lung to the relatively oxygen-poor environment of the tissue. Thus Hb
destruction may eventually lead to tissue hypoxia. Additionally, de-oxy Hb is also known to
function as nitrite reductase, reducing nitrite to form nitric oxide, a potent vasodilator [54]. This
property of Hb is essential in hypoxic vasodilation [55]. Oxidative destruction of the heme
group will also inhibit this function of Hb and may lead to vascular dysfunction.
Consequences of heme destruction
Excessive heme degradation may alter the cellular heme homeostasis which may lead to
heme deficiency. Heme plays an essential role in the normal cell physiology by acting as the
prosthetic group in several hemoproteins with housekeeping functions. In addition to acting as a
prosthetic group, free heme itself plays a number of important functions in the cell (as reviewed
in [56]).

Hemin (the oxidized form of heme) functions as a regulator of growth and

differentiation in hematopoietic and non-hematopoietic cells [56]. Heme is also known to
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modulate expression of several genes such as globin, heme oxygenase-1, TRAP and modulate
processing of pri-mRNA [56]. Additonally, heme acts as a signaling molecule and modulates the
activity of several proteins such as MAP-kinases, transcriptional factors such as hypoxia
inducing factors, Bach1 and others like HAPs [57]. Thus it is clear that heme deficiency has
severe toxic consequences.

Indeed, studies have shown that experimentally induced heme

deficiency leads to the disruption of mitochondrial membrane potential, increased oxidative
stress, disruption of Ca2+ homeostasis, and release of cytochrome c from mitochondria, events
that induce apoptosis [58, 59].
Toxicity of free iron
Generation and accumulation of free iron has been implicated in a number of
pathological conditions for example in senile diseases such as Alzheimer's disease, Parkinson's
disease as well as in atherosclerosis (as reviewed in [60]). The toxicity of free iron is attributed
to its capacity to generate highly reactive secondary free radicals through the Fenton reaction,
which eventually forms hydroxyl free radicals (·OH) from O2•- and H2O2 [61]. Fenton reaction is
essentially a disproportionation reaction as depicted in the equations 1 & 2
Fe2+ + H2O2 → Fe3+ + ·OH + OH− ……… (Eq. 1)
Fe3+ + H2O2 → Fe2+ + ·OOH + H+ …………. (Eq. 2)
The ferrous ion reacts with H2O2 to generate ·OH and is converted to ferric which can
again react with another molecule of H2O2 to regenerate the ferrous form and produce peroxide
radical (·OOH) [61]. These secondary free radicals ·OH and·OOH are highly toxic and can cause
severe damage to the host cell by oxidatively modifying amino acids, purine and pyrimidine
bases of DNA, and lipids (as reviewed in [62]).
In addition to the direct action of free iron as a source of free radical, elevated iron can
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also lead to increased bacterial infection. Since increased availability of free iron favors iron is
bacterial growth [63]. Several other transition metals such as Cobalt (Co), are also know to
function as Fenton reagent in biological systems [64]. Vitamin B12 is a common example of a
Co containing compound which is present in physiological systems.
Biology of vitamin B12
Vitamin B12 is an important water-soluble vitamin, which regulates RBC and neural cell
activity and displays antioxidant properties [65, 66]. In humans, two enzymatic pathways are
known to be dependent on vitamin B12. In the first pathway, methylmalonic acid is converted to
succinyl-CoA using vitamin B12 as a cofactor [67]. Vitamin B12 deficiency, therefore, can lead
to increased levels of serum methylmalonic acid. In the second pathway, homocysteine is
converted to methionine by using vitamin B12 and folic acid as cofactors. In this pathway, a
deficiency of vitamin B12 or folic acid may lead to an increase in homocysteine levels [68-70].
Homocysteine is a thiol containing amino acid, which at higher plasma concentrations is
correlated

with

numerous

pathological

conditions

such

as

cardiovascular

diseases,

neurodegenerative diseases, and neural tube defects [68-70]. Moreover, deficiency of vitamin
B12 has been associated with megaloblastic anemia and cognitive dysfunction in
neurodegenerative

disorders

including

Parkinson’s

and

Alzheimer’s

disease

[71].

Cyanocobalamin (Cobl) is the most common supplemental form of vitamin B12 and commonly
prescribed for subjects with deficiency of vitamin B12 in conditions such as pernicious anemia
[72]. Cobl is produced from hydroxocobalamin, naturally produced by bacteria, and used in all
natural products.

In the process of purification and separation of hydroxocobalamin from

bacteria through charcoal (a substance rich with cyanide (CN-)) columns, hydroxocobalamin
changes to Cobl form. Cobl’s structure is similar to the porphyrin tertapyrrole ring found in
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hemoproteins with Co atom residing in the center (Figure 31). The sixth coordination site,
known as the center of reactivity, is the upper/-axial ligand occupied by a cyano group (-CN).
These characteristic features make the corrin ring more flexible and less flat compared to the
porphyrin ring. A significant portion of elderly population is deficient in this water-soluble
vitamin [73]. As of yet, the interaction between Cobl and HOCl as it might occur under an
inflammatory conditions has not been studied.
Methods to lower HOCl concentration
Methods to decrease HOCl concentrations could be of substantial therapeutic benefit,
since it can prevent HOCl mediated inflammatory and pathological conditions. This can be
achieved, either by inhibiting MPO or by scavenging HOCl itself. Previous studies from our
laboratory have shown that various physiological indole compounds such as tryptophan and
melatonin and their structural analogs are effective and reversible inhibitors of MPO catalytic
activity [74-76].

These inhibitors switch the catalytic cycle of the enzyme from the

halogenations to peroxidase cycle.
In the present study, we were interested in analyzing the possible role of lycopene, a
dietary carotenoid as a potential scavenger of HOCl.
Biology of lycopene
Lycopene belongs to the carotenoid class of pigments. Since humans cannot synthesize
lycopene, dietary consumption is the sole source of lycopene in human beings. Tomatoes are the
richest source of lycopene with concentrations ranging from 0.9–4.2 mg/100 g [77].
Structurally, lycopene is a hydrocarbon, with eleven conjugated carbon-carbon double bonds and
two non-conjugated double bonds [78]. Due to the extensive hyperconjugation in the system,
lycopene achieves its typical bright red color and has a characteristic absorbance spectrum which
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can be used for its identification [78]. Of all the common dietary carotenoids, lycopene’s
concentration seems to be the highest while its tissue distribution varies widely [79].
Several

published

epidemiological

studies

showed,

lycopene

supplementation

significantly reduced the risk of several chronic pathological conditions such as, cardiovascular
disease, certain forms of cancer (e.g. prostate cancer), osteoporosis and diabetes (as reviewed in
[80]). Lycopene is a well known antioxidant. Because of the electron rich structure of the
molecule, lycopene is highly susceptible to attacks by electrophilic species. Thus lycopene is
extremely reactive towards ROS [81, 82]. For example, lycopene has been reported to be the
most effective scavenger of singlet oxygen of among ~ 600 naturally occurring carotenoids [83].
Lycopene also ameliorates oxidative stress by binding to the Antioxidative Response Element
(ARE) and upregulate several enzymes such as glutathione peroxidase, superoxide dismutase,
quinone reductase, which protect cells from the harmful effects of elevated oxidants [84-86].
Additionally, lycopene has been reported to induce apoptosis in human prostate cancer cell line
LNCap, induce cell cycle arrest at G1 phase in hepatoma cell line, modulate platelet derived
growth factor signaling and inhibit metastasis and invasion by hepatocarcinoma cells (reviewed
in [87]).
Bioactive metabolites of lycopene
Oxidative metabolites of lycopene have also been shown to possess bioactivity. For
example, lycopene metabolites have been shown to modulate a variety of cellular processes such
as increasing gap junctional communication, transactivation of nuclear receptor families (RAR,
RXR, PPAR, PXR and orphan receptors), immune modulation and as well as anti-inflammatory
[88].

Although, lycopene has been shown to possess these varied beneficial effects, the

underlying mechanism is not entirely understood. Given the significant role played by HOCl in
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cardiovascular diseases and chronic inflammatory pathologies and the protective function of
lycopene in those condition, we hypothesized that lycopene executes its protective role by acting
as a potent scavenger of HOCl.
Aims of dissertation:
1) Determine the mechanism by which HOCl mediates degradation of free heme and Hb to
generate free iron.
2) Examine the role of HOCl in destroying Cobl and generating CNCl.
3) Define the mechanism by which lycopene acts a potent scavenger of HOCl.
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CHAPTER 1
Reaction of hemoglobin with HOCl: Mechanism of heme destruction and free iron release
ABSTRACT
In this chapter we study the role of HOCl in mediating heme destruction and free iron
release from Hb and RBC. HOCl is generated by MPO, using chloride and hydrogen peroxide as
substrate. HOCl and its conjugate base (OCl-) bind to the heme moiety of Hb and generate a
transient ferric species whose formation and decay kinetics indicate it can participate in protein
aggregation and heme destruction along with subsequent free iron release. The oxidation of Hb
heme moiety by OCl- was accompanied by marked heme destruction as judged by the decrease
and subsequent flattening of the Soret absorbance peak at 405 nm. HOCl-mediated Hb heme
depletion was confirmed by HPLC analysis and in-gel heme staining. Exposure of Hb to
increasing concentrations of HOCl produced a number of porphyrin degradation products
resulting from oxidative cleavage of one or more of the carbon-methene bridges of the
tetrapyrrole ring, as identified by their characteristic HPLC fluorescence and LC-MS. A nonreducing denaturing SDS PAGE showed several degrees of protein aggregation.

Similar,

porphyrin degradation products were identified after exposure of RBC to increasing
concentration of HOCl indicating biological relevance of this finding. This work provides a
direct link between Hb heme destruction and subsequent free iron accumulation, as occurs under
inflammatory conditions where HOCl is formed in substantial amounts.
INTRODUCTION
RBC are the most common cells in the blood which derive their red color from Hb, a
protein that makes up about 92% of the RBC's dry content [89, 90]. Hb is made up of a tetramer
consisting of four protein globin subunits and four heme prosthetic groups [90]. The main
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function of Hb is to deliver oxygen from lung to peripheral tissue for cellular metabolism and
recycle carbon dioxide from tissue to the lung [91]. Hb displays high oxygen affinity with
carrying capacity ranging from 1.36 to 1.37 mL O2 per gram of Hb [92].
Within the body, Hb exists mainly in two ferrous forms: oxygenated (oxy-Hb; Hb-Fe(II)O2) and deoxygenated (Hb-Fe(II). Major interest has been focused on Hb heme destruction and
the formation of other higher oxidative states such as a ferryl porphyrin radical cation HbFe(IV)=O+π● (Compound I) and Hb-Fe(IV)=O (Compound II), and their possible role in the
development of several pathophysiological processes [49, 93, 94].

Compound I has two

oxidizing equivalents above Hb-Fe(III) while Compound II has one oxidizing equivalent above
Hb-Fe(III).

Most of the heme degradation in biological systems occurs in two different

pathways: an enzymatic pathway that requires the heme oxygenase system [49]; or a
nonenzymatic pathway that requires the interaction with reactive oxygen species (ROS),
reducing agents, or xenobiotics (as reviewed in [49]).

In the enzymatic pathway, heme

oxygenase catalyzes heme cleavage and subsequently releases the heme iron in the ferrous form,
and in a specific manner it eliminates the carbon-methene bridge of heme as CO to form
biliverdin [49, 95]. In the non-enzymatic pathways, ROS such as superoxide (O2-), hydrogen
peroxide (H2O2), and HOCl can mediate heme destruction unselectively at any position of the
heme double bonds [49, 96]. Several fluorescence and non-fluorescence heme degradation
products have been identified using NMR and/or mass spectrometry (MS) techniques [97, 98].
Furthermore, several studies have demonstrated the ability of OCl- not only to bind to the heme
moiety of several hemoproteins, but also cause heme destruction [99], protein modification and
protein aggregation [100], as well as mediate the formation of peroxidase-like activity (formation
of Compounds I and II) [101]. For example, Chapman et al. have shown that a strong non-
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covalent protein aggregation occurs when apohemoglobin and apomyoglobin was treated with
HOCl [100]. Indeed exposure of RBC to HOCl causes protein aggregation and as a result, the
lysis of these cells [33]. Protein aggregation may also disrupt normal tissue organization when
fibronectin is oxidized at sites of inflammation [102].
Hemoprotein heme destruction is extremely toxic to different organs and cells leading to
serious pathological consequences [103]. The cellular toxicity is mainly due to the generation of
free iron, which displays the capacity to participate in the further generation of ROS that
mediates cellular mitochondria poisoning, lipid peroxidation, and uncoupling of oxidative
phosphorylation [61, 103-105]. Free iron can damage blood vessels and produce vasodilation
with increased vascular permeability, leading to hypotension and metabolic acidosis [45, 46].
Hypochlorous acid is generated enzymatically by MPO, which uses H2O2 to catalyze the
two-electron oxidation of chloride (Cl−) [106]. Hypochlorous acid and its conjugate base (OCl−)
are potent oxidants that function as powerful antimicrobial agents [107]. However, under a
number of pathological conditions such as inflammatory diseases, atherosclerosis, respiratory
distress, acute vasculitis, rheumatoid arthritis, glomerulonephritis, and cancer, HOCl is
implicated in damaging the host tissue by the same mechanism used to destroy invading
pathogens [108-111].

Under many pathological conditions such as atherosclerosis,

endometriosis, and cancer, where MPO has been known to play a role, there have been reports of
significant free iron accumulation [44-46, 112, 113]. The source of this iron is still unclear, but
it is thought to be Hb released from damaged RBC at sites of vascular turbulence or in
hemorrhagic atheromatous plaques [45]. We believe there is a mechanistic link between high
HOCl and higher free iron. Our hypothesis is that the source of this iron is HOCl mediated
destruction of the heme moiety from Hb. Here we studied the reaction between purified bovine
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Hb (Hb-Fe(III) and oxy-Hb) as well as isolated human RBC with increasing HOCl
concentrations utilizing a variety of spectroscopic and analytical techniques. Our rapid kinetic
measurements demonstrate that HOCl can mediate free iron release through a mechanism that
involves formation and destruction of peroxidase-like intermediates, ultimately resulting in
oxidative cleavage of heme moiety generating fluorescent and non-fluorescent porphyrin
derivatives.

Additionally, HOCl treatment also resulted in different levels of protein

aggregation. This mechanism may accentuate tissue damage in states of inflammation.
MATERIALS AND METHODS
Materials
All the materials used were of highest purity grade and used without further purification.
Sodium hypochlorite (NaOCl), ammonium acetate (CH3COONH3), ferrozine, L-methionine,
ascorbic acid, bovine Hb, dimethylformamide, methanol and trifluroacetic acid (TFA) - HPLC
grade, were obtained from Sigma Aldrich (St. Louis, MO, USA). HPLC grade acetonitrile
(CH3CN) was obtained from EMD Chemicals Inc. (Gibbstown, NJ, USA).
Absorbance Measurements
The absorbance spectra were recorded using a Cary 100 Bio UV–visible
spectrophotometer, at 25oC, pH 7.0. Experiments were performed in a 1-mL phosphate buffer
solution supplemented with fixed amount of Hb (0.63 μM) and increasing concentration of HOCl
(0, 5, 10, 20, 40, 80, 100, 120, 160, 180, and 200 μM). After 10-minute incubation for reaction
completion, methionine (5-fold of the final HOCl concentration) was added to eliminate excess
HOCl and absorbance changes were recorded from 300 to 700 nm.
Rapid Kinetic Measurements
The kinetic measurements of HOCl-mediated Hb heme destruction were performed using
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a dual syringe stopped-flow instrument (Hi-Tech, Ltd. Model SF-61). Measurements were
carried out under an aerobic atmosphere at 10oC following rapid mixing of equal volumes of a
buffer solution containing a fixed amount of Hb (0.63 µM) and a buffer solution containing
increasing concentration of HOCl (0-200 µM). The time course of the absorbance change was
fitted to a single-exponential, (Y = 1 - e-kt), or a double-exponential (Y = Ae-k1t + Be-k2t) function
as indicated. Signal-to-noise ratios for all kinetic analyses were improved by averaging at least
six to eight individual traces. In some experiments, the stopped-flow instrument was attached to
a rapid scanning diode array device (Hi-Tech) designed to collect multiple numbers of complete
spectra (200-800 nm) at specific time ranges. The detector was automatically calibrated relative
to a holmium oxide filter, as it has spectral peaks at 360.8, 418.5, 446.0, 453.4, 460.4, 536.4, and
637.5 nm, which were used by the software to correctly align pixel positions with wavelength.
High Performance Liquid Chromatography (HPLC) analysis
HPLC analyses was carried out using a Shimadzu HPLC system equipped with a SCL10A system controller, with a binary pump solvent delivery (LC-10 AD) module and a SIL10AD auto-injector connected to a SPD-M10A diode array detector (DAD) and a RF-10A XL
fluorescence detector. Alltech 5 µm particle size, 4.6 × 150 mm reverse-phase octadecylsilica
(C18) HPLC column was used. The photodiode array detector was set at 400 nm and the
fluorescent detector was set at excitation 321 nm and emission 465 nm to monitor the
chromatogram. The column was eluted at a flow rate of 1.0 mL/min with linear gradients of
solvents A and B (A, 0.1% TFA in water; B, 0.1% TFA in 80% acetonitrile). The solvent
gradient was as follows: 0 to 10 min, 55-65% B; 10 to 14 min, 65-90% B; then the solvent B
composition were dropped down to 55% within 14 to 24 min. After treatment of Hb with HOCl,
500 µL of the reaction mixture was diluted with 500 µL of injection solvent (55% B and 45% A)
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and 50 μL were injected. At the end of the run the system was equilibrated with 45% solvent A.
For fluorescence detection the excitation and emission wavelength was set at 321 nm and 465
nm, respectively. Each sample was analyzed in triplicate. For Hb, after treatment with HOCl the
reaction mixture was filtered through Amicon Ultra-15 centrifugal filter unit with Ultracel-10
membrane (from Millipore) with a 3-kDa cut-off by centrifuging at 14000 rcf for 30 min at 4 oC.
Mass spectrometric analysis of heme degradation products
Mass spectrometry (MS) experiments were performed using an Agilent 6410 Triple
Quadrupole mass spectrometer coupled with an Agilent 1200 HPLC system (Agilent
Technologies, New Castle, DE), equipped with an electrospray source. Waters symmetry C18
column (particle size 3.5 µm; 2.1 x 100mm) (Milford, MA) was used to separate reaction
products. Solvent A was H2O with 0.1% formic acid and solvent B was acetonitrile with 0.1%
formic acid. The column was equilibrated with 80% solvent A and 20% solvent B. The gradient
was: 20-95% solvent B over 10 min; 95% solvent B for 10 min; 95-20% solvent B for 1 min; and
80% solvent A for 14 min. Five µL of the sample was injected at a flow rate of 0.25 mL/min.
Liquid chromatography electrospray ionization (LC/ESI) MS in the positive mode was
performed using the following parameters: spray voltage 4000 V, drying gas flow 10 L/min,
drying gas temperature 3250C, and nebulizer pressure 40 psi. Fragmentor voltage was optimized
using Flow injection analysis (FIA) of hematin (St. Louis, MO, USA). Optimal fragmentor
voltage was 300 V in MS2 scan mode. Mass range between m/z 200 to 900 was scanned to
obtain full scan mass spectra.
Free iron analysis
Free iron release was measured colorimetrically by using ferrozine, following a slight
modification of a published method [114]. To 100 µL of the sample (RBC-HOCl or Hb-HOCl
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reaction mixture) 100 µL of ascorbic acid (100 mM) was added. After 5 minutes of incubation
at room temperature, 50 µL of ammonium acetate (16%) and the same volume of ferrozine (16
mM) were added to the mixture and mixed well. Subsequently, the reaction mixture was,
incubated for 5-minutes at room temperature and the absorbance was measured at 562 nm. A
standard curve prepared by using ammonium Fe (III) sulfate was used for the calculation of free
iron concentration. Final concentrations of the additives are as follows, ascorbic acid-33.33 µM,
ammonium acetate-5.3 %, and ferrozine-5.3 µM.
In-gel heme staining and reducing SDS-PAGE
8 µg of Hb (from the reaction mixture) was incubated with Laemmli buffer containing 63
mM Tris–HCl (pH 6.8), 2% (w/v) SDS, 10% (w/v) glycerol, and 0.0025% (w/v) bromophenol
blue.

2-Mercaptoethanol/dithiothreitol, which interfered with the heme-staining dye, was

omitted from the Laemmli buffer. A non-reducing denaturing gel electrophoresis was performed
for 4 h at a constant voltage of 60 V on discontinuous 12% SDS gel. Gels and buffers, which
had been prepared according to Laemmli [115], were equilibrated at 4oC (by submerging the gel
apparatus in a ice bath) before electrophoresis, and electrophoresis was performed at the same
temperature. Gels were then stained either for heme with O-dianisidine/H2O2 following a slight
modification of a published method [116]. Gels were washed for 10 min in methanol/sodium
acetate (0.25 M, pH 5.0) 3/7 (v/v) and, subsequently, incubated in the dark for 20 min in a
freshly prepared solution, containing 7 parts 0.25 M sodium acetate, pH 5.0, and 3 parts 12 mM
O-dianisidine in methanol. Gels were developed by adding H2O2 to a final concentration of 1.25
M (bands developed immediately) and washed for 30 min in H2O/methanol/acetic acid 8/1/1
(v/v/v). The gels were scanned. For reducing SDS-PAGE, same procedure was followed except,
the Laemmli sample buffer had 10% 2-mercaptoethanol and the samples were boiled for 5
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minutes at 100 °C before loading.

The gels for reducing SDS-PAGE were run at room

temperature and stained with Coomassie blue.

Relative amounts of protein or heme were

estimated by densitometric analysis of the scanned image using ImageJ software from the NIH
[117].
Isolation of human red blood cells
RBC was isolated from heparinized blood collected from healthy individuals according to
a previously published method [104]. Briefly, blood sample were centrifuged at 3000 rpm for 5
min to remove the plasma and buffy coat and some of the least-dense cells containing most of
the reticulocytes. The red cell pellet was washed two times with 5 volumes of phosphatebuffered saline (PBS), pH 7.4, to make sure that all of the plasma was removed. Cells were
diluted to a hematocrit of 50% with PBS, pH 7.4. The Hb concentration was measured using
Drabkin’s reagent (Sigma Aldrich, St. Louis, MI, USA) using the manufacturer’s protocol.
HOCl treatment of red blood cells
Isolated human RBC were diluted in PBS to give an Hb concentration of 12.5 µM. this
solution of intact RBC were treated with increasing concentrations of HOCl (0- 2000 µM) for 1
hour at room temperature. Following which the reaction was stopped by addition of methionine
at 5 times the final HOCl concentration. The viability of the RBC after HOCl treatment was
evaluated by the trypan blue exclusion method [118]. After HOCl treatment, cells were lysed by
mixing with an equal volume of distilled water and incubating at room temperature for 2 minutes
and then by sonication. The cell lysates were then centrifuged at 13,000 rpm for 80 minutes to
separate the membrane debris from the cytosol. Both the cytosolic fraction and the membrane
fraction were extracted with the HPLC injection solvent and filtered through Amicon Ultra-15
centrifugal filter unit with Ultracel-10 membrane (from Millipore) with a 3-kDa cut-off by
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centrifuging at 14,000 rcf for 30 min at 4oC. The filtrate was analyzed by HPLC for the presence
of heme degradation products. RBC lysate, after HOCl treatment, was also analyzed for free
iron by ferrozine.
Solution preparation
HOCl preparation
HOCl was prepared as previously described with some modification [119]. Briefly, a
stock solution of HOCl was prepared by adding 1 mL NaOCl solution to 40 mL of 154 mM of
NaCl and the pH was adjusted to around 3 by adding HCl. The concentration of active total
chlorine species in solution expressed as [HOCl]T (where [HOCl]T = [HOCl] + [Cl2] + [Cl3−] +
[OCl−]) in 154 mM NaCl was determined by converting all the active chlorine species to OCl−
by adding a bolus of 40 µL 5 M NaOH and measuring the concentration of OCl−.

The

concentration of OCl− was determined spectrophotometrically at 292 nm (ε = 362 M−1 cm−1). As
HOCl is unstable, the stock solution was freshly prepared on a daily basis, stored on ice, and
used within one hour of preparation. For further experimentations, dilutions were made from the
stock solution using 200 mM phosphate buffer pH 7, to give working solutions of lower HOCl
concentration.
Methemoglobin solution
10 mg of lypophilized Hb powder was dissolved in 10 mL of 200 mM phosphate buffer
pH 7 to give a solution of concentration 15.5 µM. Met-Hb solution prepared in this manner was
kept on ice and used within one hour.
Oxyhemoglobin solution
10 mg of lyophilized Hb powder was dissolved in 1 ml of 200 mM phosphate buffer pH
7.0. A few crystals of sodium dithionate was added and mixed well. The solution was aspirated
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by pipette to saturate with oxygen. Excess sodium dithionate was removed by passing the
solution through a Sephadex G-25 M column (Amersham Biosciences).

The prepared

oxyhemoglobin solution was kept on ice and used within an hour of preparation.

The

concentration of oxy-Hb in the stock solution was determined spectrophotometrically at 577 nm
(ε = 14.6 mM− 1 cm− 1/heme) [120].
RESULTS
HOCl treatment significantly reduce viability of RBC senescence
Human RBC was treated with various molar ratios of HOCl:Hb for 1 hour at room
temperature and their viability was evaluated using the trypan blue exclusion technique (as
specified in the Materials and Methods section). Our results show that the RBC viability did not
significantly change up to 20:1 HOCl:Hb ratio, but above that there was remarkable decrease in
RBC viability, with complete loss of viability occurring at 120:1 HOCl:Hb ratio (Figure 3).
Figure 3: HOCl treatment causes decrease in RBC
viability. Isolated human RBC adjusted to Hb concentration of
12.5 µM was treated with different molar ratios of HOCl (0 to
160 fold) for 1 hour at room temperature. The viability of the
cells was assayed by the trypan blue exclusion technique. The
results are expressed as percent of cells alive as a function of
molar ratio of HOCl:hemoglobin. For details see Materials and
Methods section. The above result is an average of three
independent experiments and the error bars represents the
standard error of measurement.
Free iron release and accumulation of heme degradation products from RBC after HOCl
treatment
Human RBC was treated with different molar ratios of HOCl:Hb and the formation of
fluorescent heme degradation products were studied using HPLC both in the membrane (data not
shown) as well as the cytosolic fraction (Figure 4). HPLC chromatograms show the presence of
mainly three distinct fluorescent peaks in the membrane and as well as the cytosol. These
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Figure 4. Treatment of human RBC with HOCl
leads to the generation of fluorescent heme
degradation products in the RBC cytosol. Isolated
human RBC adjusted to Hb concentration of 12.5
µM was treated with a range of HOCl:Hb molar
ratios (0 to 160 fold HOCl) and analyzed by HPLC,
as detailed in the Materials and Methods section.
The fluorescent detector was set at excitation 321 nm
and emission 465 nm. The molar ratio of the
HOCl:Hb used for treatment is mentioned in inset of
each panel. The above set of chromatograms is a
representative of three independent experiments.

products were not observed in the HOCl untreated control but were only seen in HOCl treated
samples. Comparison of the retention times of the fluorescent products observed from RBC with
those obtained when Hb was treated with HOCl reveals that they were very similar. Thus it can
be concluded that these fluorescent products were generated by HOCl mediated heme destruction
of Hb in RBC. Free iron accumulation as assayed by ferrozine method showed a similar trend as
observed for Hb-HOCl i.e. a linear increase as a function of HOCl concentration (Figure 5).
Figure 5. Release of free iron from isolated human RBC
following treatment with HOCl. Isolated human RBC
adjusted to Hb concentration of 12.5 µM was treated with
different molar ratios of HOCl (0 to 160 fold) for 1 hour at
room temperature. Free iron was assayed colorimetrically
using ferrozine (for details see Materials and Methods
section). The above result is an average of three independent
experiments and the error bars represents the standard error of
measurement.

23
Optical spectroscopy and stopped-flow measurements
We first characterized OCl- binding to Hb-Fe(III) and its subsequent effects on Hb heme
destruction. The visible spectrum of methemoglobin (met-Hb) displayed a Soret absorbance
peak centered at 405 nm with absorbance shoulders at 500 and 631 nm, indicative of a ferric
heme. Exposure of a fixed amount of Hb (0.6 µM) to increasing concentration of HOCl caused
Hb heme destruction, as judged by the loss and flattening of the Soret peak region. Incubation of
Hb with 40 µM of HOCl caused 50 % decrease in the Soret band, whereas the addition of 200
µM of HOCl led to a complete flattening of the Soret absorbance peak indicating heme
destruction. We next, utilized diode array stopped-flow spectrophotometry to continuously
monitor and identify species that formed upon mixing the protein solution with phosphate buffer
supplemented with increasing concentration of HOCl. All HOCl concentrations employed were
in larger molar excess to Hb to ensure pseudo first order conditions. Figure 6 shows spectra
collected over time for the reaction of Hb-Fe(III) with HOCl (200 µM final). As shown in
Figure 6A, the starting spectrum recorded after 0.05s is characteristic of Hb-Fe(III), which
displays a Soret absorbance peak centered at 405 nm with absorbance shoulders at 500 and 631
nm, indicative of a ferric heme. This was followed by a buildup of a transient intermediate,
whose spectrum was characterized by absorbance peak at 415, 533, and 567 nm, attributable to
Hb–Fe(III)-OCl complex formation (traces 2-5). This transition species then decayed to form
another transient intermediate whose spectral features match those of authentic Hb ferryl
complex (Hb-Fe(IV)=O complex, Compound II) via rapid initial formation of Compound I
(Figure 6B). Compound II possesses a characteristic Soret absorbance peak at 420 nm that is
easily distinguished from the Soret absorbance peaks of both Hb-Fe(III) and Hb-Fe(III)-OCl, as
shown in Figure 6A and 6B. The oxidation of Compound II by HOCl was accompanied by a
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Figure 6. Interaction of met-Hb with HOCl
leads to the transient formation of Compound
II, before heme destruction.
Absorbance
spectra were recorded by diode array stoppedflow when a phosphate buffer solution (0.20 M,
pH 7.0) containing 1.25 μM met-Hb was rapidly
mixed with a buffer solution containing 400 μM
HOCl, at 10 °C. Graph A contains spectra
collected 0.02, 0.048, 0.138 and 0.198 s after
initiation of the reaction, which shows the
accumulation of Hb-Fe(III)-OCl complex. The
inset shows the accumulation of Hb-Fe(III)-OCl
complex as judged by the transition of the Soret
absorbance peak with a distinct isobestic point at
412 nm. Graph B contains spectra collected
0.198, 0.15, 0.298, 0.398, and 0.498 s after
initiation of the reaction, which shows the
conversion of Hb-Fe(III)-OCl to Compound II.
The inset shows the accumulation of Compound
II as judged by the transition of the Soret
absorbance peak from 405 to 420 nm. Graph C
contains spectra collected 1.5, 9.5, 34.5, 89.5,
149.5, and 599.5 s after initiation of the reaction,
which shows Compound II heme destruction.
Arrows indicate the direction of spectral change
over time. The experiments shown are
representative of three.
remarkable decrease and subsequent flattening in the Soret absorbance region, suggesting heme
degradation (Figure 6C). These spectral changes may also suggest that the majority of Hb was
converted to Fe(IV)=O complex before heme destruction. The occurrence of two defined sets of
isosbestic points (at 412 and 414 nm) at two different time frames suggest that the Hb heme
degradation succeeds through subsequent intermediate products and indicate that at least three
phases of the reaction can be distinguished (Figure 6).
To examine the kinetics of interaction between HOCl and Hb-Fe(III) and determine rate
constant for the various forms of Hb, we monitored the changes in absorbance at two different
wavelengths; 405 and 420 nm.

These wavelengths were chosen to facilitate the direct
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examination of HOCl not only as a ligand, but also as a mediator for heme destruction.
Formation of Hb-Fe(III)-OCl was monitored by following the decrease in absorbance at 405 nm
which also showed the formation of Compound II. The influence of HOCl on Compound II
decay was also monitored by spectral changes occurring at the isosbestic point 412 nm.
Therefore, the formation of Compound II, if any, following interaction of HOCl with Hb, would
not have been seen. The influence of HOCl on the kinetics of Compound II buildup, duration,
and its exhaustion were monitored by following the both increase and decrease in absorbance at
420 nm. Experiments were carried out under aerobic conditions following rapid mixing of fixed
amount of Hb-Fe(III) solution with various concentration of HOCl (25, 50, 100, 150, and 200
µM, final concentration).
At all of the HOCl concentrations tested, there was a monophasic decrease in absorbance
at 405 nm attributed to buildup of Hb-Fe(III)-OCl complex formation, followed by a slower,
essentially monophasic decrease attributed to heme destruction. As shown in Figure 7A, the plot

Figure 7. Plots of observed rate constants of various
intermediates that formed upon mixing of met-Hb against
increasing concentrations of HOCl. (Graph A) The observed
rate of Fe(III)–OCl complex formation was monitored by
following the decrease in the absorbance at 405 nm. (Graph B)
The observed rate constant of the buildup of Compound II was
followed by monitoring the increase in absorbance at 420 nm.
(Graph C) The observed rate constant of heme destruction was
monitored by following the decrease in absorbance at 405 and
420 nm. The experiments were carried out as for Figure 6. The
rates plotted are the averages of three or four separate
experiments..
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of kobs versus HOCl concentration was linear, with a positive intercept indicating that the reaction
is reversible and follows a one step mechanism. The kinetic parameters for HOCl binding, kon
and koff, estimated from the slope and intercept, respectively, were found to be 0.008 µM-1s-1 and
0.2 s-1. Only the slow phase was observed when the same reaction was monitored at 420 nm.
HOCl significantly accelerated the rate of heme destruction in a concentration dependent
fashion. A plot of HOCl concentration versus rate of Compound II destruction demonstrated
linear kinetics with y-intercept close to zero and yielded a second order rate constant of 6 X 10-5
µM-1s-1 (Figure 7C). The accelerated rate of Compound II destruction in the presence of HOCl
indicates that it also binds and oxidized the porphyrin ring.
Based on spectra of Figure 6B and previous work with Hb, we followed the buildup of
Hb Compound II and its decay at 420 nm. As shown in Figure 6B, formation of Hb Compound
II appeared rapidly and required 1.5 s to reach completion, whereas its decay was very slow and
reach completion in the next 600 s.

In both cases, the spectral changes were essentially

monophasic and fitted well to a single exponential function. For the rate of Compound II
formation, the plot of kobs versus HOCl concentration was linear with an intercept at y-axis close
to zero, indicating that reaction is irreversible with a second order rate constant of 0.02 µM-1s-1
(Figure 7B). The rate of the second step is essentially identical to the slow phase that was
observed at 405 nm consistent with only Compound II destruction occurring under this
condition. For heme destruction, the plot of the kobs as a function of HOCl concentration was
also linear with a y-intercept close to zero, giving a second order rate constant of 6.0 X 10-5µM-1s-1
(Figure 7C).

Together, these results indicate that HOCl-mediated Hb heme destruction is

relatively slow and occurs upon complete conversion of Hb-Fe(III) to Compound II.
In order to facilitate comparison, identical experiments were repeated with oxy-Hb. The
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Figure 8. Oxy-hemoglobin heme oxidation
and subsequent heme destruction mediated
by HOCl. Absorbance spectra were recorded by
diode array stopped-flow when a phosphate
buffer solution (0.20 M, pH 7.0) containing 1.25
μM oxy-Hb was rapidly mixed with a buffer
solution containing increasing concentrations of
HOCl, at 10 °C. The top shows heme oxidation
when the protein solution was rapidly mixed
with a buffer solution supplemented with 20 μM
HOCl; spectra were collected 0.5, 1.5, 24.5, and
599.5 s after initiation of the reaction. The inset
shows the transition of the Soret absorbance
peak from 415 (oxy-Hb) to 405 nm (met-Hb).
The bottom shows Hb heme destruction when
the oxy-Hb solution was rapidly mixed with 400
μM HOCl; spectra were collected 0.5, 1.5, 6.5,
19.5, 44.5, 89.5, 199.5, and 599.5 s after
initiation of the reaction. Arrows indicate the
direction of spectral change over time. The data
are representative of three independent
experiments.

absorbance spectrum of oxy-Hb is characterized by its Soret absorbance peak centered at 412 nm
and two weaker well-resolved absorption maxima at 541 and 577 nm. Addition of HOCl to oxyHb solution initially caused a rapid small decrease in absorbance at 412 nm with time, followed
by instant buildup of a transient species, whose spectrum was characterized by absorbance peak
at 405, (upper panel of Figure 8). These spectral features clearly showed that the majority of
oxy-Hb was oxidized and converted essentially to Hb-Fe(III) in the first 150 s of initiating the
reaction. The decrease in absorbance was best fitted to a one exponential function with pseudo
first order rate constant of 0.023 s-1 for 10 µM HOCl. At higher concentrations of HOCl the
change in absorbance was very small to accurately measure the rates. This transient intermediate
was characterized by a Soret peak at 405 nm and a visible band at 537 and 576 nm. These
spectral changes suggest that OCl- is coordinated to the ferric heme iron and form a low spin six-
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coordinate Fe(III)-OCl complex which is associated with the destabilization of the Hb heme
moiety after complete conversion to Compound II. This can be determined by the decrease and
flatting in the Soret peak region from 350 nm to 450 nm. This interpretation is based on the
previously reported spectral changes that showed addition of H 2 O 2 to Hb leads to the
accumulation of Compound II via rapid initial formation of Compound I. Monitoring the
spectral decrease at 412 nm indicated that the reaction was monophasic at lower concentrations
of HOCl (< 150 µM) and at higher concentrations (≥ 150 µM ) the reaction was biphasic and
best fitted to a two exponential function with pseudo-first order rate constant of 0.029 and 0.003
s-1 for 150 µM HOCl. About 50% of the total absorbance change at 150 µM HOCl was
associated with the slow phase. To determine the kinetic parameters of the reactions, the

Figure 9. Plots of observed rate constants of various
intermediates that formed upon mixing of oxy-Hb against
increasing concentrations of HOCl. (Graph A) The observed
rate constant of the Fe(III)–OCl complex formation, as in Figure
7, was monitored by following the decrease in absorbance at 405
nm. (Graph B) The observed rate constant of the buildup of
Compound II was monitored by the following the increase in
absorbance at 420 nm. (Graph C) The observed rate constant of
heme destruction was monitored by following the decrease in
absorbance at both 405 and 420 nm. The rates plotted are the
averages of three or four separate experiments.

reactions were repeated at different HOCl concentration. For the first phase, the plot was linear
with a positive intercept at the y-axis, indicating that OCl- binding is reversible with kon and koff,
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estimated from the slope and intercept of 0.044 µM-1s-1 and 1.2 s-1, respectively (Figure 9A). For
the formation of compound II the plot was linear with an intercept at the y-axis close to zero
yielding a second order rate constant of 0.024 µM-1s-1 (Figure 9B). The third phase of the
reaction attributed to the process of heme destruction was found to be irreversible as indicated by
the linear plot with y-intercept close to zero yielding a second order rate of 2.0 X 10-5 µM-1s-1
(Figure 9C).
HOCl-mediated heme destruction, protein aggregation and free iron release in hemoglobin
As HOCl is thought to oxidize the heme moiety of Hb, we examined whether these
spectral transformations that are apparent from our UV–visible spectral analysis may represent
oxidation, free iron release, and subsequent protein aggregation. To investigate how the
flattening in the Soret absorbance peak at 405 nm, in HOCl treated samples, is related to Hb
heme depletion, we analyzed the heme content in Hb (6.25 µM) after treatment with increasing
molar excess of HOCl, by in-gel heme staining. Figure 10A shows the heme content following

Figure 10. In-gel heme staining confirms that
HOCl treatment causes heme destruction from
hemoglobin. A: Hb (6.25 μM) was treated with
160 fold of HOCl for 10 minutes at room
temperature and in-gel heme staining was
performed by o-dianisidine-H2O2 method, as
detailed in Materials and Methods section. B: Nonreducing SDS PAGE analysis of the same samples
as in stained with coomassie blue for protein. The
above figure is a representative of three
independent experiments.

HOCl treatment compared to untreated control. By comparing the band intensity of the
untreated control it can be said that the treatment with HOCl leads to appreciable loss in heme
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content in Hb confirming our previous spectrophotometric studies. It was also observed that Hb
undergoes aggregation as evidenced by the higher molecular weight bands observed in the
coomassie staining (Figure 10B). To study this phenomenon in more detail we performed
reducing SDS-PAGE (Figure 11). The Hb monomer band intensity decreases slightly until quite
Figure 11. HOCl concentration dependent depletion
of hemoglobin monomer and subsequent formation
of high molecular weight aggregates. 6.25 µM of Hb
dissolved in phosphate buffer was treated with different
molar ratios of HOCl (0 to 256 fold HOCl) for 10
minutes at room temperature. A: SDS-PAGE of HOCl
treated Hb. After HOCl treatment, samples were run in
12% SDS-PAGE under reducing condition. The first
lane on the left has the standard molecular weight
markers,the masses (Kd) of the marker proteins closest
to hemoglobin monomer, dimer and tetramer have been
shown. The arrows indicate the expected position of the
monomer, dimer, trimer and tetramer bands of
hemoglobin. The molar of HOCl;Hb with which the
sample was treated is shown at the top of each well.
The figure shown is a representative of three
independent experiments. B: Densitiometric scanning
of the gel image was performed as mentioned in the
Materials and Methods section. The percentage of
monomer (as calculated by the monomer band
intensity) after HOCl treatment (solid line) and the ratio
between oligomer/monomer band intensity (represented in the graph as Oligomer/Monomer, as
dotted line) is plotted as a function of HOCl concentration. The results shown are an average of
three independent experiments and the error bars represents the standard error of measurement.
near the 1:32 Hb:HOCl ratio, followed by a steep plunge until 1:160 Hb:HOCl ratio after which
it saturates. In contrary, the monomer:oligomer band intensity showed a steady increase till
1:160 Hb:HOCl ratio after which it saturates. Higher amounts of dimers were formed at 1:32
and 1:64 ratios of Hb:HOCl. At concentration higher than that (1:32 or 1:64) dimer content
decreased but high molecular weight oligomers were formed. With the largest amounts of
HOCl, the distinct pattern of aggregation disappeared, producing smears over the entire length of
the lanes (as visualized with coomassie stain). This could be attributed either to the formation of
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aggregates that were too large to enter the separating gel, or to fragmentation. Kettle and
coworker obtained similar aggregation patterns when apo-Hb and apomyoglobin were treated
with HOCl [100]. Strong, non-covalent interactions between protein chains has been assumed,
which could apply to this work. Thus, we conclude that HOCl-mediated protein aggregation of
Hb occur independent of heme presence. Free iron accumulation when assayed by ferrozine
method showed a linear increase as a function of HOCl concentration (Figure 12).
Figure 12. Release of free iron from hemoglobin
following treatment with HOCl. 6.25 µM of
hemoglobin was treated with different molar ratios of
HOCl (0 to 320 fold) for 10 minutes at room
temperature. Free iron was assayed colorimetrically
using ferrozine (for details see Materials and Methods
section). The above result is an average of three
independent experiments and the error bars represents
the standard error of measurement.

HPLC analysis of heme degradation products from Hb
Heme by itself does not have any intrinsic fluorescence, but porphyrin derivatives
generated due to oxidative fragmentation of heme have an intrinsic fluorescence. We exploited
this property to analyze the heme fragmentation pattern after HOCl treatment of Hb. Figure 13
shows the chromatograms when Hb was treated with different molar ratios of HOCl. We
incubated a fixed amount of Hb (6.3 µM) with increasing molar ratios of HOCl (1:64, 1:160 and
1:256). When Hb was reacted with HOCl there was a progressive accumulation of new heme
degradation products (as a function of HOCl concentration) eluting at earlier time (Figure 13).
HOCl treatment led to the formation of four different fluorescent degradation products with
retention times of 1.8, 3.09, 5 and 8 minutes respectively. The appearance of newer earlier
eluting peaks in the chromatograms could be due to the formation of degradation products with
decreasing hydrophobicity generated by fragmentation of the tetrapyrrole ring of the heme.
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Figure 13. Treatment of hemoglobin with HOCl leads to
the generation of fluorescent heme degradation
products. Hemoglobin (6.25 µM) was treated with a range
of HOCl:hemoglobin molar ratios (0 to 256 fold HOCl)
and analyzed by HPLC, as detailed in the Materials and
Methods section. The fluorescent detector was set at
excitation 321 nm and emission 465 nm. The molar ratio of
the HOCl:Hb used for treatment is mentioned in inset of
each panel. The above set of chromatograms is a
representative of three independent experiments.

LC-ESI-MS of heme fragmentation products
LC/ESI/MS in the positive mode was utilized to elucidate HOCl-mediated reaction
products of Hb. We subjected the reaction products of varying concentrations HOCl with Hb and
with RBC (membrane and cytosolic fractions). The majority of the products were tentatively
identified by detecting the molecular ions [M + H]+ from the most abundant peaks following
LC/MS. The molecular weights were then compared with the proposed structures with the
previously identified products and/or depending on the chemical reactivity of HOCl with carboncarbon double bonds [97, 98, 106]. These cleavage products were classified into four major
categories according to the degree of oxidation and their cleavage position within the heme
molecule. Group 1 consists of compound with the intact tetrapyrrole ring system with the iron
but with oxidative modification in the terminal carbons. m/z 638 (Figure 14) eluting at 8 min
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Figure 14. LC-ESI-MS of the reaction of
RBC with HOCl (Hb:HOCl ratio 1:120) The
reaction mixture from the membrane fraction
was separated by reverse-phase HPLC and
subjected to ESI/MS in the positive mode as
described under Materials and methods. The
major reaction product produced an intense
peak at 8 min. Examination of the MS spectrum
revealed that the [M + H]+ ion had a m/z 638.
(A) The extracted ion chromatogram (EIC) and
(B) the MS spectrum of this peak are depicted.

identified from Hb:HOCl 1:120 reaction mixture (identified from RBC membrane fraction) is an
example of this class of compound. Group 2 consists of tripyrrole derivatives, which resulted by
oxidative cleavage of the tetrapyrrole ring of heme by HOCl. Compounds identified that fall in
group 2 include m/z 388, from RBC cytosolic fraction (Hb:HOCl and 1:20 and 1:160), eluting at
7.8 min. Group 3 consists of dipyrrole derivatives of heme. There are three compounds that fall
under this category m/z 421 (Figure 15) eluting at 11.1 min (identified from Hb:HOCl 1:128,

Figure 15. LC-ESI-MS of the reaction
of Hb with HOCl (Hb:HOCl ratio
1:128). The reaction mixture was
separated by reverse-phase HPLC and
subjected to ESI/MS in the positive mode
as described under Materials and
methods. The major reaction product
produced an intense peak at 11 min.
Examination of the MS spectrum
revealed that the [M + H]+ ion had a m/z
421. (A) The extracted ion chromatogram
(EIC) and (B) the MS spectrum of this
peak are depicted.
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Figure 16. LC-ESI-MS of the reaction of
RBC with HOCl (Hb:HOCl ratio 1:80)
identified from RBC cytosolic fraction.
The reaction mixture was separated by
reverse-phase HPLC and subjected to
ESI/MS in the positive mode as described
under Materials and methods. The major
reaction product produced an intense peak at
8 min. Examination of the MS spectrum
revealed that the [M + H]+ ion had a m/z
315. (A) The extracted ion chromatogram
(EIC) and (B) the MS spectrum of this peak
are depicted.
1:288, 1:320) , m/z 315 (Figure 16) identified from RBC cytosol fraction (Hb:HOCl 1:40) and
m/z 405 identified from Hb. Group 4 consists of mono-pyrrole derivatives; m/z 244 identified
from RBC cytosol is an example of this class of compound. Group 4, consists of compounds
that have resulted from extensive oxidation and cleavage of the tetrapyrrole ring, example of
compounds in this group include m/z 449, and m/z 594 (Figure 17). Table 1 shows, the structures
of all the heme degradation compounds tentatively identified by LC-MS.

Figure 17. LC-ESI-MS (positive mode) of the
reaction of RBC with HOCl (Hb:HOCl ratio
1:80) identified from RBC membrane
fraction. The reaction mixture was separated by
reverse-phase HPLC and subjected to ESI/MS as
described under Materials and methods. The
major reaction product produced an intense peak
at 8 min. Examination of the MS spectrum
revealed that the [M + H]+ ion had a m/z 594.
(A) The extracted ion chromatogram and (B) the
MS spectrum of this peak are depicted.
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Table 1: Structures of different heme degradation products as tentatively identified by LCMS following treatment of Hb and isolated human RBC with HOCl

DISCUSSION
Hb is the most abundant hemoproteins in humans with an average of 750 g in adult [121].
RBC develops in bone marrow, which is rich in Hb (20 mM). RBC have a limited life span
(~120 days) before their components are recycled by macrophages [49]. Using a combination of
biochemical, physiological, and kinetic approaches, we showed that HOCl oxidizes oxyHb,
binds to the heme iron, and mediates Hb heme destruction thereby generating more toxic free
iron, and heme degradation products, resulting in protein aggregation. In order to perform its
physiological function, Hb has to tightly bind molecular oxygen (in the oxygen-rich atmosphere
of the lungs) and release it in the relatively oxygen-poor environment of the tissues. Therefore,
we propose that the oxidation of oxy-Hb/met-Hb by HOCl may play an important role in altering
the protein function by destabilizing Fe-O2 complex, causing heme destruction, or forming Hb
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Compounds I and II. Met-Hb and Hb ferryl intermediates are inactive form of Hb, which cannot
bind oxygen.

Accumulation of these species in the blood could result in tissue hypoxia,

impeding the normal function of Hb. Oxy-Hb and met-Hb also react with other ROS such as O2and H2O2 to produce Compounds I and II [101]. Similarly, a molar excess of H2O2 has been
reported to degrade the heme moiety of Hb and other related hemoproteins such as cytochrome c,
releasing iron from heme [50-52]. The dissociation and the destruction of heme moiety may also
be enhanced by damage to the globin, which binds the heme [122]. Thus, increased HOCl levels
or the deficiency of potent scavengers of HOCl such as taurine, glutathione, and lycopene [106,
123, 124] may contribute to inflammation, cancers and other related disorders by increasing
catalytically active free iron levels.
A general kinetic scheme of how HOCl interacts with Hb intermediates incorporated into
the classic peroxidase-like cycle is illustrated in Figure 18. The capacity of HOCl to influence

Figure 18. Kinetic model of HOCl mediated heme destruction
both the oxidation state transition of Hb heme iron and the stability of heme moiety supports the
notion that HOCl displays multiple functions over the time course of the reaction. The ability of
OCl- to serve as a ligand for met-Hb was directly demonstrated employing diode array stoppedflow methods. OCl- is a relatively bulky molecule and its binding to the sixth coordinate position
on the distal Hb heme group is limited by the close proximity of surrounding amino acids. It has
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been thought that the heterolytic cleavage of the O-Cl bond in an Fe(III)-OCl intermediate
preferentially occur at neutral conditions to degrade HOCl and form a ferryl porphyrin radical
cation, Compound I [125].

Compound I is highly unstable intermediate due its ability to

withdraw one electron from another molecule of OCl-, forming Compound II.

Because

Compound I formation is slower than its decay to Compound II, Compound I cannot be detected.
Thus, the observed absorbance changes should reflect the alteration in Compound II
accumulation, duration, and decay. Such a species has been proposed to be formed in catalase
and LPO during reaction with HOCl, as well as, during inactivation of horseradish peroxidase by
cyclopropanone hydrate [126-128]. It seems likely that only Compound II was degraded by
HOCl. Heme degradation process is spectrally distinguishable by the flattening in the heme
Soret region which can be explained by the release of the heme prosthetic group, the heme
oxidation and destruction, or combination of both. Spontaneous breakage or weakening of the
natural imidazole nitrogen ligand provided by the distal histidine (His58) can be explained by the
negative trans effect of OCl-, which in this case, favors cleavage of the iron-nitrogen bond
located on the opposite side of heme iron or through the formation of the Hb-Fe(III)-OO•- radical
that is formed through the formation of Compound II [49]. Our HPLC and mass spectrometric
results clearly show a direct correlation between Hb oxidation and the formation of fluorescent
and non-fluorescent degradation products as well as free iron accumulation.
Our kinetic measurements indicated that Compound II is the predominant species formed
prior to heme destruction, providing direct evidence for involvement of Compound II in heme
destruction. This conclusion is in full agreement with Nagababu and Rifkind who showed that
substances that react with Hb Compound II, such as sodium sulfide and peroxidase substrate
prevent H2O2-mediated heme degradation [129].

Our results show that HOCl not only
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accelerates the formation of Compound II, but also enhances Hb heme destruction. Hb heme
destruction is an irreversible process, relatively slow and associated with free iron release and
protein aggregation.
The direct reaction between oxy-Hb complex and HOCl first involves oxidation of heme
iron from ferrous to ferric state. Thus, Hb can no longer bind oxygen but it can bind an OClmolecule. Because significant Fe(III)-OCl complex formation can be seen immediately after
oxy-Hb oxidation, it seems likely that OCl- molecule that mediated heme oxidation is still
retained in the heme pocket and binds to the ferric heme iron immediately after oxygen release.
This may contribute to the binding rate constant enhancement which in turn influences the
alteration in the intermediate distributions during the reaction progression, but otherwise the
kinetic parameters of Compound II formation, duration, and heme destruction were almost
similar to those obtained for met-Hb with HOCl (Figures 7A & 9A).
Heme depletion was confirmed by in-gel heme staining, which clearly showed loss of
heme from Hb following HOCl treatment. HOCl mediated heme destruction was also associated
with increased free iron release and a buildup of three new fluorescent products. The excitation
and emission wavelengths of these fluorescent products are similar to those observed when H2O2
reacted with Hb, and indistinguishable from those obtained when isolated human RBC were
treated with HOCl. It is interesting to note that these fluorescent bands are observed when oxyHb, hematin, as well as protoporphyrin IX was treated with increasing concentrations of HOCl
(data not shown). Thus, the cleavage of porphyrin ring is occurring independent of the metal
center. The destruction of heme molecule leads to the liberation of heme iron as determined by
the ferrozine method.

In this respect, Hb may serve as a source of free iron at sites of

inflammation when HOCl is elevated. The free iron generated by Hb destruction may induce
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oxidative stress and make it highly toxic, as it can rapidly react with H2O2 and molecular oxygen
to produce free radicals [103]. Toxicity of free iron can damage blood vessels and produce
vasodilation with increased vascular permeability, leading to hypotension and metabolic acidosis
[46, 105]. Recent studies have shown that catalytically active MPO, the major generator of
HOCl, and its oxidative species are present in human atherosclerotic lesions [130], promote lipid
peroxidation, DNA strand breaks, and modification or degradation of biomolecules, eventually
leading to cell death [131]. It has also been shown that iron accumulates in atherosclerotic
lesions in a catalytically active form [130].
HPLC and LC-MS analysis indicate that multiple fluorescent and non-fluorescent
cleavage products were generated when heme was degraded by HOCl. A total of ten cleavage
products have been identified based on their mass signals through the treatment of Hb and RBC
with different concentrations of HOCl. The degree of degradation of heme (as assessed by the
number and chain lengths of the various oxidative metabolites of heme degradation products)
depends mainly on the ratio of HOCl to heme, suggesting that multiple molecules of HOCl are
required per molecule of heme. The proposed chemical mechanism for the HOCl mediated
cleavage of heme moiety is shown in Figure 19A.
In this model, HOCl can randomly attack any of the four carbon methene bridges
between the adjacent pyrrole ring and forms a chlorinated adduct, which by releasing of chloride,
forms an epoxide or aminal. The epoxide gives rise to a hydroxylated compound with the
hydroxyl group being attached to the carbon-methene bridge of the tetrapyrrole moiety, where
the initial attack by HOCl occurred. Attack by another hydroxyl group to this carbon leads to the
formation of a vicinal diol (two hydroxyl groups attached to two adjacent carbon atoms).
Cleavage of the vicinal diol leads to the formation of two carbonyl compounds. The cleavage of
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Figure 19. Proposed chemical mechanism for the HOCl mediated cleavage and subsequent
methylation of the heme degradation products.
the vicinal diol can either occur through a homolytic cleavage forming two carbonyl compounds,
or in the presence of iron, through the formation of dioxetane intermediate by a heterolytic two
electron process (shown in Figure 19A in red) [132]. The aldehydes that are generated may
further be oxidized by HOCl to form carboxylic acid, through a mechanism described previously
[106]. Cleavage of the C=C bond is not only limited to the carbon-methene bridge, but it can
also occur at the terminal C=C bond, leading to the formation of formaldehyde (Figure 19B).
This single carbon aldehyde can be oxidized to formic acid by the electrophilic addition of HOCl
[133]. The formaldehyde thus generated is used for the formation of methyl esters as seen in
some of the structures (Figure 19B).
Taken together, the results of our studies suggest that the HOCl-mediated cleavage
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reaction of heme and the degree of oxidation could occur non-selectively at any position of the
heme double bonds independent of HOCl concentration. Many of the metabolites in Table 1
have been reported, as their metabolic pathways were investigated, whereas other cleavage
products and their functions are either not yet fully explained or not mentioned before in the
literature [97, 98].

H2O2 have been shown to be a major player in non-enzymatic heme

destruction. For example, Fisher and Muller were the first to show that H2O2 can mediate the
destruction of heme to dipyrrolic compounds [49]. Similar reaction with ferric heme has shown
the generation of CO and biliverdin IX which subsequently reacts with another H2O2 molecule
yielding bilirubin [49, 134].

Comprehensive mechanistic studies by Brown et al., have

suggested that the active species that attacks the heme moiety is HO2- rather than H2O2 (through
the reaction H2O2 < === > HO2- + H+) and generates pigments through a reaction that involves
the formation of ferriheme-peroxidase intermediates [50, 97, 135].

Schaefer et al. have

identified six major products generated by the reaction of hemin with H2O2 by using mass
spectroscopy

and

NMR,

four

dipyrrolic

propentdyopents,

hematic

acid,

and

methylvinylmaleimide [97]. Groves et al. demonstrated the formation of a formal perferryl
species from the reaction of heme and H2O2 [136].

This species has been implicated in the

random cleavage of the porphyrin ring to form dipyrroles and monopyrroles. Nagababu and
Rifkind have shown that the reaction of heme and hemin with H2O2 produces two fluorescent
products similar to that observed when Fe(II)-Hb reacts with H2O2 [50]. They have concluded
that the metal center is essential to form these fluorescent products [50]. From these results, one
may naturally come to the conclusion that HOCl behaves as a stronger oxidant with a higher
oxidative potential than H2O2 and other oxidants for heme destruction.
Reducing denaturing SDS-PAGE revealed a different profile of protein aggregation as a
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function of HOCl concentration. Previously, Chapman et. al. [100] have studied aggregation of
apo-Hb (heme free Hb) upon exposure to HOCl.

From extensive biochemical and mass-

spectrometric studies they concluded that apo-Hb on exposure to HOCl undergoes aggregation
and produces a regular series of high molecular weight oligomers [100]. This change in the
protein structure in Hb was facilitated by the formation of protein carbonyls and possibly
chloramines, along with methionine oxidation, which altered the protein folding and
subsequently the secondary/tertiary structure of the protein. The process of aggregation was due
to non-covalent interaction between the exposed hydrophobic areas on neighboring molecules
that associate to form dimers and higher-molecular mass aggregates [100]. Our results with
intact Hb shows similar pattern of protein aggregation in reducing SDS PAGE.

The only

difference being that we observed a distinct dimer band, even at higher HOCl-Hb ratios, while
Chapman et. al. reported that a higher HOCl-Hb ratios the dimer was not observed [100]. This
difference could be attributed to the presence of heme in our reaction system. As shown in our
results, Hb with intact heme when treated with HOCl undergoes heme destruction which releases
free iron. Thus, we conclude that HOCl-mediated protein aggregation of Hb occurs independent
of heme presence. Previous, studies by Lucana et. al. [137] has shown that free iron can
mediated protein cross linking by dityrosine formation. Additionally, Nagy et. al. [138] have
shown that Hb isolated from atheromatous lesions have a higher dityrosine content. Thus it can
be presumed that in our reaction HOCl treatment of intact Hb causes free iron release which
mediates dityrosine formation which is evident by the presence of dimmer bands even at higher
HOCl-Hb ratios. Detailed study of this phenomenon is currently under process in our laboratory.
This process could lead to the formation of aggregated proteins at sites of inflammation where
MPO activity and subsequently HOCl generation is enhanced and may contribute to tissue
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injury.

Aggregated proteins are formed during aging [139], in diabetes [140] and in

neurodegenerative diseases, including Creutzfeldt–Jacob disease, Huntington's disease,
Alzheimer's disease and Parkinson's disease [140-142].
Several studies have shown that RBC with abnormal Hb is usually exposed to sustained
oxidative stress from both exogenous and endogenous sources of ROS. Exposure to oxidative
stress is associated with enhanced Hb autoxidation, accumulation of iron in membranes, and
increased membrane damage, which in sum results in shorter life span for pathological RBC. It
is worth noting that the mechanisms of these changes have not been explored yet. Previous
studies by Vissers et. al. [143] have shown that HOCl exposure of human RBC caused a dose
dependent depletion cellular GSH content.

Thus destruction of GSH in RBC after HOCl

treatment makes them more vulnerable towards oxidative insults since glutathione peroxidaseglutathione system cannot function efficiently. Our results showed that HOCl treatment of
isolated intact human RBC caused a HOCl dose dependent senescence, formation of fluorescent
heme degradation products along with a concomitant increase in free iron level. Our HPLC
analysis revealed that at least three fluorescent heme degradation products are found in the
isolated cytosolic and membrane fractions with overwhelming majority of those found in cytosol
fraction. Similar studies with H2O2 have shown that 90% of the fluorescent heme degradation
products are found to be localized on the RBC membrane [144]. Additionally these products are
not transferred from the cytosol to the membrane. A plausible explanation for this finding is that
cytosolic H2O2 is easily scavenged by the cytosolic antioxidant system. On the contrary, H2O2
generated by the membrane associated Hb is not, leading to increased heme destruction in the
membrane. HOCl treatment have been reported to cause a dose dependent depletion of the
cytosolic glutathione level in RBC [143] thereby inactivating the glutathione peroxidase-
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glutathione cycle. This makes HOCl a stronger oxidant (to destroy Hb) in the RBC cytosol.
Previous studies by Nagababu et al. have shown that H2O2 formed in association with Hb
autoxidation reacts with Hb and initiates a cascade of reactions that results in heme degradation
with the formation of two fluorescent emission bands and the release of iron [50, 129]. A 5.6
fold increase in fluorescence was found in red cells from sickle transgenic mice that expressed
exclusively human globins when compared to red cells from control mice [145].

Heme

degradation was also increased 3.5 fold in β-thalassemic mice generated by deletion of murine β
major [145].
Therefore, inhibiting MPO and/or eliminating its final products may play a beneficiary
role in biological system in reducing the free iron release mediated by HOCl. Recently we have
shown that melatonin, tryptophan, and tryptophan analogs display the potential capacity in
inhibiting MPO, the major sources of HOCl [146-149].

Mechanistic studies indicate that

melatonin and other indole compounds inhibit MPO activity by switching the catalytic pathway
from peroxidase to catalase-like by acting as 1e- substrates for MPO Compounds I and II [146149]. In related studies, we have also shown that peroxynitrite in combination of H2O2 in a low
chloride concentration environment inhibit MPO through a mechanism that involves heme
destruction and iron release [117].
In summary, the reaction between HOCl with different forms of Hb occurs through a
complex pathway involving the sequential generation and decay of oxoferryl intermediates.
HOCl reacts with the heme moiety of Hb and causes heme degradation and the release of free
iron. HOCl could also mediate different degrees of protein aggregation in the globin molecule.

45
CHAPTER 2
Mechanism of hycpochlorous acid mediated heme destruction and free iron release
ABSTRACT
In addition to its role as a prosthetic group, free heme by itself has numerous functions
such as modulating cell signaling pathway and, controlling growth and differentiation of
hematopoietic cells. Here, we show that HOCl, a potent neutrophil generated oxidant, can
mediate destruction of free heme (Ht) and the heme precursor, protoporphyrin IX (PPIX). Ht
display a broad Soret peak centered at 365 and 394 nm, indicative of the presence of monomer
and μ-oxo-dimer. Oxidation of Ht by HOCl was accompanied by a marked decrease in the Soret
absorption peak and release of free iron. Kinetic measurements showed that the Ht-HOCl
reaction was triphasic. The first two phases were HOCl concentration dependent and attributable
to HOCl binding to the monomeric and dimeric forms. The third phase was HOCl concentration
independent, and attributed to Ht destruction with the release of free iron. HPLC and LC-ESIMS analyses of the Ht-HOCl reaction revealed the formation of a number of degradation
products, resulting from the cleavage or modification of one or more carbon-methene bridges of
the porphyrin ring. Similar studies with PPIX showed that HOCl also mediated tetra-pyrrole
ring destruction.

Collectively, this work demonstrates the ability of HOCl to modulate

destruction of heme, through a process that occurred independent of the iron molecule that
resides in the porphyrin center. This phenomenon may play a role in HOCl-mediated oxidative
injury in pathological conditions.
INTRODUCTION
Heme is a planar metalloporphyrin compound with an iron (Fe) atom chelated at the
center of the porphyrin macrocycle (Figure 20A) [150]. The Fe atom plays a pivotal role in the
functioning of the heme, such as molecular recognition and chemical selectivity [150]. The
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Figure 20. Structures of Ht (1A) and PPIX (1B).
important role of free heme is its ability to serve as a signaling molecule and a regulator of
growth and differentiation of hematopoietic and non-hematopoietic cells [151]. It also serves as
a prosthetic group in several hemoproteins [151]. The heme moiety of hemoproteins forms the
catalytic site where the stepwise oxidation of substrate takes place [152, 153]. During enzymatic
catalysis, the heme prosthetic group plays a critical role in supporting one or more of following
functions: substrate binding and storage (Hb), electron transfer (mitochondrial electron transport
system), bond formation and breaking (catalase and peroxidases), product release (nitric oxide
synthases), and protein conformational change (Hb) [151]. The reduced form of hemoprotein
reacts with molecular oxygen and generates superoxide anion (O2•-) [154, 155]. Due to the
absence of steric hindrance effects from the neighboring protein, these redox reactions are faster
with free heme than with hemoprotein model compounds and, therefore, free heme mediates the
generation of more toxic components than hemoprotein model compounds
In the biological system, heme degradation occurs in two different pathways: the
enzymatic pathway that requires the presence of heme oxygenase system; and non-enzymatic
pathway mediated through reactive oxygen species (ROS) such as O2•- and hydrogen peroxide
(H2O2) [49]. Heme deficiency mediated by the acceleration in heme destruction and consequent
dysregulation of the cellular heme homeostasis may lead to pathological conditions such as
Alzheimer’s disease and aging [59]. Heme destruction is extremely toxic to different organs and
cells leading to serious pathological consequences [151]. The toxicity of heme destruction is
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mainly due to the free iron release, which can generate ROS and mediate cellular mitochondrial
dysfunction, lipid peroxidation, and uncoupling of oxidative phosphorylation [62, 156, 157].
Free Fe damages blood vessels and causes vasodilation with increased vascular permeability,
leading to hypotension and metabolic acidosis [46, 158].
Under many pathological conditions such as atherosclerosis, endometriosis, and cancer,
where MPO has been known to play a role, there have been reports of significant free Fe
accumulation [44, 46, 112, 113, 158, 159]. The source of this Fe is remains unclear, but it is
thought to be Hb [158]. Myeloperoxidase uses H2O2 to catalyze the two-electron oxidation of
chloride (Cl-) to generate HOCl [133]. Hypochlorous acid and its conjugate base (OCl−) are
potent oxidants that function as powerful antimicrobial agents [107]. However, under a number
of pathological conditions such as inflammatory diseases, atherosclerosis, pulmonary fibrosis,
acute vasculitis, rheumatoid arthritis, glomerulonephritis, and cancer, HOCl is implicated in
damaging the host tissue by the same mechanism used to destroy invading pathogens [108-111].
We believe that there is a mechanistic link between high HOCl and higher free Fe levels. In the
current work, we studied the reaction between purified bovine hematin (Ht-Fe(III)) and
protoporphyrin IX (PPIX) (Figure 20B) with HOCl utilizing a variety of spectroscopic and
analytical techniques. Our rapid kinetic measurements demonstrate that HOCl can mediate free
Fe release through a mechanism that involves heme destruction ultimately resulting in oxidative
cleavage of heme moiety generating fluorescent and non-fluorescent porphyrin derivatives. This
mechanism may contribute to vascular endothelial dysfunction that is induced by oxidative stress
in various inflammatory diseases.
MATERIALS AND METHODS
Materials
All the materials used were of highest purity grade and used without further purification.
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Sodium hypochlorite (NaOCl), ammonium acetate (CH3COONH3), ferrozine, L-methionine,
ascorbic acid, hematin (Ht), protoporphyrin IX (PPIX), dimethylformamide, methanol and
trifluroacetic acid (TFA) - HPLC grade, were obtained from Sigma Aldrich (St. Louis, MO,
USA). HPLC grade acetonitrile (CH3CN) was obtained from EMD Chemicals Inc. (Gibbstown,
NJ, USA).
Absorbance Measurements
The absorbance spectra were recorded using a Cary 100 Bio UV–visible
spectrophotometer, at 25°C, pH 7.0. Experiments were performed in a 1-mL phosphate buffer
solution supplemented with fixed amount of Ht (2.5 μM) and increasing concentration of HOCl
(0-100 μM). After 10 minute incubation for reaction completion, methionine (5-fold of the final
HOCl concentration) was added to eliminate excess HOCl and absorbance changes were
recorded from 300 to 700 nm.
Rapid Kinetic Measurements
The kinetic measurements of HOCl-mediated Ht destruction were performed using a dual
syringe stopped-flow instrument obtained from Hi-Tech, Ltd. (Model SF-61). Measurements
were carried out under an aerobic atmosphere at 10C following rapid mixing of equal volumes
of a buffer solution containing a fixed amount of Ht (2.5 µM) and a buffer solution containing
increasing concentration of HOCl. The time course of the absorbance change was fitted to a
single-exponential, (Y = 1 - e-kt), or a double-exponential (Y = Ae-k1t + Be-k2t) function as
indicated. Signal-to-noise ratios for all kinetic analyses were improved by averaging at least six
to eight individual traces. In some experiments, the stopped-flow instrument was attached to a
rapid scanning diode array device (Hi-Tech) designed to collect multiple numbers of complete
spectra (200-800 nm) at specific time ranges. The detector was automatically calibrated relative
to a holmium oxide filter, as it has spectral peaks at 360.8, 418.5, 446.0, 453.4, 460.4, 536.4, and
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637.5 nm, which were used by the software to correctly align pixel positions with wavelength.
High Performance Liquid Chromatography (HPLC) analysis
HPLC analyses was carried out using a Shimadzu HPLC system equipped with a SCL10A system controller, with a binary pump solvent delivery (LC-10 AD) module and a SIL10AD auto-injector connected to a SPD-M10A diode array detector (DAD) and a RF-10A XL
fluorescence detector.

An Alltech 5 µm particle size, 4.6 × 150 mm reverse-phase

octadecylsilica (C18) HPLC column was used. The column was kept at 27°C. The photodiode
array detector was set at 400 nm and the fluorescent detector was set at excitation 321 nm and
emission 465 nm to monitor the chromatogram. The column was eluted at a flow rate of 1.0
mL/min with linear gradients of Buffers A and B (A, 0.1% TFA in water; B, 0.1% TFA in 80%
acetonitrile). The solvent gradient was as follows: 0 to 10 min, 55-65%B; 10 to 14 min, 65-90%
B; then the buffer B composition dropped down to 55% within 14 to 24 min. After treatment of
Ht with HOCl, 500 µL of the reaction mixture was diluted with 500 µL of injection solvent (55%
B and 45% A) and 50 μL were injected. At the end of the run the system was equilibrated with
45 % solvent A. Under these conditions, Ht eluted at around 19 min and was identified from the
characteristic spectral signal from the Diode Array Detector. For fluorescence detection, the
excitation and emission wavelength were set at 321 nm and 465 nm, respectively. Each sample
was analyzed in triplicate.
Mass spectrometric analysis of heme degradation products
Mass spectrometry (MS) experiments were performed using an Agilent 6410 Triple
Quadrupole mass spectrometer coupled with an Agilent 1200 HPLC system (Agilent
Technologies, New Castle, DE), equipped with an electrospray source. A waters symmetry C18
column (particle size 3.5 µm; 2.1 x 100mm) (Milford, MA) was used to separate reaction
products. Solvent A was H2O with 0.1% formic acid and Solvent B was acetonitrile with 0.1%
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formic acid. The column was equilibrated with 80% solvent A and 20% solvent B. The gradient
was: 20-95% solvent B over 10 min; 95% solvent B for 10 min; 95-20% solvent B for 1 min; and
80% solvent A for 14 min. 5 L of the sample was injected at a flow rate of 250 L/min.
Liquid chromatography electrospray ionization (LC/ESI) MS in the positive mode was
performed using the following parameters: spray voltage 4000 V, drying gas flow 10 L/min,
drying gas temperature 3250C, and nebulizer pressure 40 psi. Fragmentor voltage was optimized
using Flow Injection Analysis with Ht. Optimal fragmentor voltage was 300 V in MS2 scan
mode. Mass range between m/z 200 and m/z 900 was scanned to obtain full scan mass spectra.
Free iron analysis
Free iron release was measured colorimetrically using ferrozine, following a slight
modification of a published method [114]. To 100 µL of the sample (Ht-HOCl reaction mixture)
100 µL of ascorbic acid (100 mM) was added.

After 5 minutes of incubation at room

temperature, 50 µL of ammonium acetate (16%) and the same volume of ferrozine (16 mM)
were added to the mixture and mixed well. Subsequently, the reaction mixture was incubated for 5minutes at room temperature and the absorbance was measured at 562 nm. A standard curve prepared

by using ammonium Fe (III) sulfate was used for the calculation of free iron concentration. Final
concentrations of the additives are as follows, ascorbic acid-33.33 µM, ammonium acetate-5.3
%, and ferrozine-5.3 µM.
Solution preparation
HOCl preparation
HOCl was prepared following the same method as mentioned in Chapter 1.
Hematin solution
Ht solution was prepared by dissolving 11.3 mg of porcine Ht in 100 mL of 100 mM
NaOH [160]. The solution was stored in a dark bottle at 10°C and was stable for a month. For
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experiments, the stock solution was diluted in 200 mM phosphate buffer pH 7 to get working
solutions of lower concentration.
Protoporphyrin IX solution
Approximately

1

mg

of

solid

protoporphyrin

IX

was

dissolved

in

methanol:dimethylformaide (1:1). Since protoporphyrin IX is light sensitive, care was taken not
to expose the stock solution to light and was used within one hour of preparation.

For

experiments, the stock solution was diluted in 200 mM phosphate buffer pH 7 to get working
solutions of lower concentration.
RESULTS
HOCl mediated heme destruction is a triphasic process
To examine the kinetics of interaction between HOCl and Ht, we utilized diode array
stopped flow spectrophotometry. Rapid kinetic studies were initially performed under pseudo
first order condition where the HOCl concentrations employed were in large molar excess of Ht.
The visible spectrum of Ht displayed a broad Soret absorbance peak with two shoulders centered
on 360 and 394 nm indicative of a mixture of two forms, Ht monomer and Ht µ-oxo dimmer,
respectively, as previously reported [161]. The influence of HOCl on the kinetics of Ht-OCl
complex formation and subsequent heme destruction were examined following rapid mixing of a
buffer solution supplemented with 2.5 µM (final) Ht with equal volume of a buffer solution
Figure 21. Ht has a broad Soret peak with absorbance
shoulders on 360 nm and 394 nm. Diode array stoppedflow experiment was carried out by mixing Ht (2.5 µM,
final) with HOCl (70 µM, final) in phosphate buffer solution
(0.2 M, pH 7, 10 °C) and successive full wavelength scans
(from 300-700 nm). The arrows indicate the direction of the
spectral changes. The times (in s) after which successive
spectral scans was obtained is mentioned in the figure. The
above figure is a representative of three independent
experiments.
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supplemented with increasing concentration of HOCl (0- 400 µM, final). Figure 21 shows the
time course for the formation of Ht-Fe(III)-OCl and heme destruction by monitoring the
absorbance changes from 300-700 nm. The figure shows spectral traces collected at 3, 7, 19, 51,
121, 237 and 595 second after mixing. The decrease in absorbance that takes place at either 360
or 394 nm indicated that the reaction is triphasic in nature (Figure 22). The change in

Figure 22. The reaction between Ht and HOCl is
triphasic in nature. Ht (2.5 µM, final) was reacted
with HOCl (80 µM, final) in phosphate buffer solution
(0.2 M, pH 7, 10 °C) and the decrease in absorbance at
394 nm was monitored as a function of time. The inset
shows the first very fast phase of the reaction. The
above figure is a representative of three independent
experiments.

absorbance takes place in the first 1 s of the reaction is shown in the Figure 22 inset and is
attributed to the binding of the HOCl to the heme iron in the monomeric form of Ht, leading to
the formation of Ht-Fe(III)-OCl complex. The build-up of Ht-OCl complex was best fitted to a
single exponential function, giving an apparent second order combination rate constant (kon) of
0.095 µM-1s-1 and dissociation rate constant (koff) of 3.9 s-1 calculated from the slope and yintercept, respectively. The second phase of the reaction that takes place in the next 30 s was
attributed to the formation of Ht(III))-OCl complex through the binding of HOCl to the heme
iron of the dimeric form of Ht. Plotting the pseudo first order rates for this phase as a function of
HOCl concentration revealed that this phase was also reversible in nature but with a
comparatively slower rate than the first phase, kon= 0.0037 µM-1s-1 and koff= 0.3 s-1. The
subsequent decrease in absorbance observed was also fit to a single exponential function and
found to be HOCl independent with a rate constant of 0.005 s-1. This decrease in absorbance was
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attributed to the heme destruction/cleavage of the tetrapyrrole ring (Figure 23). Together, these
results indicate that the build-up of Ht-Fe(III)-OCl complex is relatively fast, biphasic, and occur
with a much faster than the heme destruction. The change in absorbance at 394 nm shows
change differed in the amplitude of the three phases but otherwise it follows the same kinetics.

Figure 23. Second order rates for the three different
phases of the reaction between Ht and HOCl. AFormation of Fe-OCl complex from Ht monomer. BFormation of Fe-OCl complex from Ht µ-oxo dimer. CHOCl mediated heme degradation. Experiments were
performed at least three times and the curves fitted
individually and the averages of the results were plotted.
The error bars represent the standard error of
measurement.

HOCl treatment causes release of free iron from hematin
Ht (25 µM) was incubated with different molar ratios of HOCl (1:1, 2:1, 4:1, 8:1, 16:1,
32:1 and 40:1; Ht:HOCl) for 10 minutes, and free iron released was measured using ferrozine
assay as detailed in Materials and Methods section. The free iron increased in a linear manner
and showed signs of saturating only when the ration of HOCl:Ht of 16:1. The inflection point in
the two straight lines was at 11:1 indicating eleven molecules of HOCl are required to
completely destroy one molecule of Ht and release the iron (Figure 24).
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Figure 24. Release of free iron from Ht following HOCl
treatment. Ht (25 µM) was reacted with increasing molar
ratios of HOCl and the accumulation of free iron was
measured by ferrozine method. The inflection point (which
occurs at 11:1 HOCl:Ht ratio) is marked by the dotted line.
The above result is the average of three independent
experiments and the error bars represent the standard error of
measurement.

HPLC analysis of heme degradation products obtained after HOCl treatment
Ht does not have an intrinsic fluorescence but previous reports have shown that different
porphyrin degradation products generated due to cleavage of the tetrapyrrole moiety have an
intrinsic fluorescence. We decided to exploit this property to study and characterize the
degradation products of the Ht-HOCl reaction. Ht (25 µM) was treated with increasing molar
ratios of HOCl ( 1:1, 1:2, 1:6) and HPLC separation coupled with fluorescence detection
(excitation 321 nm and emission 465 nm) was employed to monitor the formation of the
fluorescent heme degradation products (Figure 25). From the HPLC chromatograms we can see

Figure 25. Treatment of Ht with HOCl leads to the
formation of fluorescent heme degradation products. Ht
(25 µM) was reacted with a range of molar ratios of HOCl
and the reaction products were analyzed by HPLC with
fluorescent detection (excitation 321 nm and emission 465
nm). The HOCl:Ht ratios with which the samples were
treated are mentioned in each panel. The above figure is a
representative of three independent experiments.
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that reaction of Ht with HOCl lead to the progressive accumulation of at least five major
compounds eluting at earlier time.

The retention times of the five different fluorescent

degradation products were 1.9, 2.9, 3.3, 5.2 and 8.5 minutes respectively. The appearance of
newer earlier eluting peaks in the chromatograms could be due to the formation of degradation
products with lesser hydrophobicity generated by fragmentation of the tetrapyrrole ring of the
heme.
Role of iron in HOCl mediated cleavage of the tetrapyrrole-ring
To understand the role of the metal center (iron in our case) in HOCl mediated cleavage
of the tetrapyrrole ring, we analyzed the reaction between PPIX with HOCl by HPLC. PPIX (25
µM) was reacted with different molar ratios of HOCl (1:16 and 1:60) and HPLC was performed
in similar manner (Figure 26). Comparison of the retention times of the fluorescent products
observed from PPIX with those obtained when Ht was treated with HOCl revealed that they are
very similar. Thus it can be concluded that the presence or absence of the metal center does not
play a role in the pattern of the cleavage of the porphyrin ring.

Figure 26. Treatment of PPIX with HOCl leads to the
formation of similar fluorescent degradation products.
PPIX (25 µM) was reacted with a range of molar ratios of
HOCl and the reaction products were analyzed by HPLC
with fluorescent detection (excitation 321 nm and emission
465 nm). The HOCl:PPIX ratios with which the samples
were treated are mentioned in each panel. The above figure
is a representative of three independent experiments.
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LC-ESI-MS of the heme degradation obtained from Ht and PPIX after HOCl treatment
The majority of the products were tentatively identified by detecting the corresponding
molecular weight and comparing the proposed structures with the previously identified products
and/or owing to the chemical reactivity of HOCl with carbon-carbon double bonds [97, 133,
162]. Mass spectrometric analysis revealed that HOCl can randomly cleave the tetrapyrrole ring
at any C=C double bond including the carbon-methene bridge, the terminal carbon in the side
chain and even in the pyrrole ring itself. Oxidative modification of the C=C resulted in the
formation of epoxide, carboxylic acid, chlorination, hydroxylation and methyl ester formation.
We have been able to tentatively identify 6 fragments from Ht and 10 fragments from PPIX. m/z
= 659, 449, 437, 425, 421, 409 were identified from both Ht and PPIX. Whereas, m/z = 615,
581,577, 563 were identified only from PPIX. Table 1 shows the structures for all the different
degradation products that we have been able to identify. Figure 27 shows the Extracted Ion

Figure 27. EIC and MS spectrum of the
product m/z 421 identified by LC-ESI-MS
(positive mode) from HOCl treatment of Ht
and PPIX. The reaction mixture was separated
by reverse-phase HPLC and subjected to
ESI/MS as described under Materials and
Methods. The major reaction product produced
an intense peak at 11 min. Examination of the
MS spectrum revealed that the [M + H]+ ion
had a m/z 421.
(A) The extracted ion
chromatogram and (B) the MS spectrum of this
peak are depicted.
Chromatogram (EIC) and MS spectra for m/z 421. This product was observed from both Ht and
PPIX and is an example where HOCl treatment induced formation of methyl ester. We propose
two alternative structures that match this molecular weight. Figure 28 shows the chlorinated
oxidation fragment that was obtained from PPIX. Figure 28A shows the EIC for m/z 615. We
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can see two different products eluting at around 11 min and 12 min, respectively. The MS
spectrum for both the peaks (Figure 28B and 28C) revealed the presence of one chlorine atom as
the ion intensity of the [M + H + 2]+ ion is approximately 40% of [M + H]+, indicating a chlorine
isotope pattern. We have been able to identify one chlorinated product matching this molecular
weight. m/z 581 is an example of hydroxylated fragment generated from HOCl treatment of
PPIX (Figure 29). The EIC for this product is shown in Figure 29A, we can see there are three

Figure 28. EIC and MS spectrum of the
product m/z 615 identified by LC-ESI-MS
(positive mode) from HOCl treatment of
PPIX. The reaction mixture was separated by
reverse-phase HPLC and subjected to ESI/MS
as described under Materials and Methods. The
major reaction product produced an intense
peak at 11 min (labeled as 1) and 12 min
(labeled as 2). Examination of the MS spectrum
revealed that the [M + H]+ ion had a m/z 615.
(A) The extracted ion chromatogram and (B)
and (C) the MS spectrum of peak 1 and 2,
respectively, are depicted.

Figure 29. EIC and MS spectrum of the
product m/z 581 identified by LC-ESI-MS
(positive mode) from HOCl treatment of
PPIX. The reaction mixture was separated by
reverse-phase HPLC and subjected to ESI/MS as
described under Materials and Methods. The
major reaction product produced three intense
peak at 10.25, 11.25 and 13.5 min, respectively.
Examination of the MS spectrum revealed that
the [M + H]+ ion had a m/z 581. (A) The
extracted ion chromatogram and (B) the MS
spectrum of this peak are depicted.
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isomers of these products. Figure 29B-D shows the MS spectra for the three individual peaks.
We have been able to assign structures two of the three isoforms for this molecular weight.
DISCUSSION
Although increased levels of HOCl are typically observed in the plasma and tissues of
individuals with various inflammatory diseases, [134-137] the link between elevated levels of
HOCl and heme destruction has yet to be fully elucidated. Using a combination of variety of
spectroscopic and mass spectrometric techniques, we have shown that HOCl not only binds to
the monomeric and dimeric forms of Ht to generate a penta-coordinate high-spin complex HtFe(III)-OCl, but also mediates Ht destruction and subsequent iron release. HPLC and LC-MS
analysis showed that exposure of Ht to increasing concentrations of HOCl gave a range of
metabolites resulting from oxidative cleavage of one or more C=C (Table 2). HOCl may directly
mediate the destruction of Ht by nonselective cleavage at any double bond position in
nonenzymatic manner.

HOCl-mediated Ht destruction occurred independent of Ht iron as

similar products are observed for PPIX. A total of 16 cleavage products have been identified
based on their mass signals through the treatment of Ht/PPIX solutions with a range of HOCl
concentrations. The degree of oxidation, the amount of Ht and PPIX degradation mainly depend
on the HOCl concentration, suggesting that multiple molecules of HOCl are required to destroy
one molecule of Ht or PPIX.
Using rapid kinetic measurements, OCl- was shown to bind to both monomeric and
dimeric forms, consistent with the formation of the corresponding high-spin penta-coordinate
Fe(III)-OCl complex. Stopped-flow analyses demonstrated that the binding of OCl- to both
forms followed a simple reversible single-step mechanism with a remarkable decreased rate of
OCl- binding of monomeric versus dimeric forms. A simple explanation that could account for
this result would be that the dimeric form dissociates and releases oxygen that allows
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Table 2. Structures of heme degradation products tentatively identified by LC-ESI-MS
after HOCl treatment of Ht and PPIX

accessibility of OCl- to the heme iron. Exposure of Ht to saturating amounts of HOCl caused a
decrease and flattening of the Soret absorbance peak region, suggesting Ht destruction. Since the
formation of the Ht-Fe(III)-OCl occur faster than heme destruction, the porphyrin destruction
could occur in two distinct pathways.
First, through the subsequent effect of OCl- binding to the iron center, in this case
through the formation of ferrly complex followed by the binding of OCl- to the Ht iron center
[151] (Figure 30). In this case, the heterolytic cleavage of the O-Cl bond in an Ht-Fe-OCl
intermediate preferentially occur, at neutral conditions to degrade HOCl and form a ferryl
porphyrin radical cation Ht-Fe(IV)=O intermediate. This intermediate is highly unstable due to
its ability to withdraw one electron from another molecule of OCl-, forming Ht-Fe(IV)=O
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complex. Ht-Fe(IV)=O complex is unstable in the presence of HOCl which could be destroyed
through the formation of Ht-Fe(III)-OO- radical (Figure 30). Under these circumstances, the

Figure 30. A general kinetic model to explain the interaction of Ht with HOCl leading to
the heme degradation and free iron release.
formation rate of the ferryl intermediates are comparable or slower that the decay therefore the
buildup of these intermediates can not been seen, and the conversion of Ht-Fe(IV) to Ht-Fe(III)OO- is the rate limiting step and occurs independent of the HOCl concentration. This pathway
could be excluded since the heme destruction take place independent of the presence of Fe.
Indeed, our results showed that the treatment of PPIX with increasing concentration of HOCl
generates a number of PPIX degradation products. This pathway could apply for a number of
hemoprotein model compounds, where the heme serves as the catalytic sites of the proteins [96,
163, 164]. The Ht destruction process is relatively slow, irreversible in nature, and occurs
independent of HOCl concentration.
Second, Ht destruction can occur through the direct attack of HOCl to the tetrapyrrole
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ring through a mechanism similar to what shown in Figure 19.
Our current results clearly show that HOCl can non-enzymatically mediated heme
destruction and subsequent liberation of free iron. Indeed, our HPLC and mass spectrometric
results show a direct link between Ht oxidation and the formation of fluorescent and nonfluorescent degradation products as well as free iron accumulation. Ferrozine assays showed that
11 molecules of HOCl required for the destruction of one molecule of Ht. The cleavage of the
C=C bond is not only limited to the carbon-methene bridge, but it can also occur at the terminal
C=C bond and also within the C=C in the pyrrole ring itself.

Based on the pattern

of cleavage, we

have

are

able

to

categorize

the

compounds

we

been

able

to

identify tentatively by LC-MS to 4 major groups. Group 1 consists of compounds which have
the intact tetrapyrrole ring with modification (methyl ester formation) only in the terminal C=C
bond, e.z. m/z 577.

Group 2 consist of compounds resulting from subsequent oxidative

modification of the Group 1 compounds, and they include compounds with modification
(epoxide, hydroxylation, chlorohydrin formation) in one or more carbon methene bridge and a
terminal C=C bond. Examples of compounds in this group are m/z 659, 615 and 581. The
compound with m/z 581, has three isomers with different retention times, we have been able to
assign structures to two of them (Table 2). Group 3 consists of dipyrrolic compounds that are
formed by the oxidative cleavage of the tetrapyrrole moiety at two carbon methene bridges, e.z.
m/z 437, 425, 421, 409, 405. From our LC-MS studies it can be said that there are two isomers
for m/z 425, and we have been able to propose three different possible structures, which are
shown in Table 2.

Group 4 consists of compounds resulting from extensive oxidative

modifications of group 3 compounds, resulting in opening of the tetrapyrrole ring e.z. m/z 449,
409.
H2O2, like HOCl, can mediate heme destruction unselectively at any of the four-meso
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carbon bridges, but to lesser degree [97, 98]. Several fluorescent and non-fluorescent heme
degradation products have been identified using NMR and/or mass spectrometric techniques
upon the treatment of hematin with H2O2 solution [97, 98]. Previous studies by Schaefer et. al.
and He et. al. have shown that several oxidants such as cumene hydroperoxide, NADPH and O2
(in the presence of NADPH-P450 reductase) and H2O2 can mediate destruction of free heme as
well as heme from hemoprotein [97, 98]. These oxidants have been shown to cleave the
tetrapyrrole ring in the carbon-methene bridges forming the corresponding mono, dipyrrole
derivatives. Our LC-MS studies also support these observations. Our results show that in
addition to the cleavage occurring at the carbon methene bridges, HOCl can also cleave the C=C
in the pyrrole ring itself, causing ring opening. Examples of such extensive modifications are
observed for m/z 449 and m/z 425. One possible structure proposed for m/z 425 is a di-pyrrole
derivative where one pyrrole ring has been cleaved open, but the other one is intact (Table 2),
whereas m/z 449 is a dipyrrole derivative where both the pyrrole rings have been cleaved opened
include m/z 449 (Table 2). Additionally HOCl mediated oxidative modifications are not only
limited to the C=C in the carbon-methene bridges or the pyrrole ring but it can also occur at the
terminal C=C of the leading to the release of a single carbon, formaldehyde molecule, which is
used to form the methyl esters as observed in some of the structures (e.z. m/z 659, 437, 421 and
405). These distinctive features (cleavage of the pyrrole ring and oxidative modification of the
terminal C=C) points to the fact that HOCl is a more potent oxidant, causing extensive
destruction of the heme tetra-pyrrole moiety. In the enzymatic pathway, heme oxygenase system
catalyzes heme cleavage and subsequently releases the heme iron in the ferrous form, and in a
specific manner it eliminates the α-methene bridge carbon of heme as carbon monoxide (CO) to
form either bilivedrin, or if the heme is still attached to a globin, verdohemoglobin [49, 165]. In
sum HOCl is a more potent oxidant than H2O2 and heme oxygenase in mediating heme
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destruction and extensive modification of the heme degradation products.
Heme deficiency mediated by the enhancement in heme destruction or altered cellular
heme homeostasis may lead to pathological conditions such as Alzheimer’s disease and aging
[59, 166, 167]. Heme destruction is extremely toxic to various organs and cells leading to
serious pathological consequences [168, 169].

Heme insufficiency promotes collapse of

mitochondrial membrane potential, oxidative stress, disruption of Ca++ homeostasis, and release
of cytochrome C from mitochondria, events that induce cell aging and programmed cell death
(apoptosis) [58]. Heme deficiency can also affect the function of translational initiation factor 2
kinase (heme-regulated elF2a kinase; HRI), a functional hemoprotein that severely modifies the
phenotype of both erythropoietic proporphyria and beta-thalassemia [170]. Our results show that
heme deficiency mediated through the HOCl heme destruction pathway is associated with
accumulation of free iron. The toxicity of cellular free iron is due to its capacity to participate in
the further generation of ROS, such as the O2-, H2O2, and the hydroxyl radical (OH), that
mediate cellular mitochondria dysfunction, lipid peroxidation, and oxidative phosphorylation
uncoupling [61, 103, 105]. Free iron damages blood vessels and produce vasodilation with
increased vascular permeability, leading to hypotension and metabolic acidosis [46, 158].
In this respect, inhibiting MPO and/or eliminating its final products may play a
beneficiary role in biological systems in reducing the free iron release mediated by HOCl.
Recently we have shown that melatonin, tryptophan, and tryptophan analogs display the potential
capacity in inhibiting MPO, the major source of HOCl [146-149]. Mechanistic studies indicate
that melatonin and other indole compounds inhibit MPO activity by switching the catalytic
pathway from peroxidase to catalase-like by acting as 1e- substrates for MPO Compound I and II
[146-149]. In related studies, we have also shown that peroxynitrite in combination of H2O2 in a
low chloride concentration environment inhibit MPO through a mechanism that involves heme
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destruction and iron release [117].
To summarize, the present studies demonstrate a heretofore unrecognized bidirectional
relationship Ht/PPIX and HOCl. Using a combination of biochemical and kinetic approaches,
we show that Ht may serve as a catalytic sink for HOCl, limiting its bioavailability and function.
HOCl not only served as a ligand for heme iron, but also mediated Ht destruction by direct
interaction with the tetra-pyrrole ring. The damage caused to heme by HOCl can be greatly
amplified by the liberation of free redox-active iron. However, it should be noted that HOCl can
also mediate destruction of the heme moiety of hemoproteins [163, 164]. Thus, HOCl generated
from MPO may participate in similar reactions at sites of inflammation where leukocytes,
peroxidases, and enhanced HOCl concentration are observed. Taken together, this work may
elucidate in part the mechanism of heme deficiency under certain pathological conditions where
MPO activity is elevated.
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CHAPTER 3
The reaction of HOCL and cyanocobolamin: corrin destruction and the liberation of
cyanogen chloride
ABSTRACT
In this chapter we extend our work and show the ability of HOCl to mediate the
destruction of metal-ion derivatives of tetrapyrrole macrocyclic rings, such as cyanocobalamin
(Cobl) a common pharmacological form of vitamin B12. Overproduction of hypochlorous acid
(HOCl) has been associated with the development of variety of disorders such as inflammation,
heart disease, pulmonary fibrosis and cancer through its ability to modify different biomolecules.
HOCl is a potent oxidant generated by the myeloperoxidase-hydrogen peroxide-chloride system.
Cyanocobalamin is a water soluble vitamin which plays an essential role as an enzyme cofactor
and antioxidant, modulating nucleic acid metabolism and gene regulation. It is widely used as a
therapeutic agent and supplement, because of its efficacy and stability. In this report, we
demonstrate that while Cobl can be an excellent antioxidant, exposure to high levels of HOCl
can overcome the beneficial effects of Cobl and generate proinflammatory reaction products.
Our rapid kinetic, HPLC and mass spectrometric analyses showed that HOCl can mediate corrin
ring destruction and liberate cyanogen chloride (CNCl) through a mechanism that initially
involves -axial ligand replacement in Cobl to form a chlorinated derivative, hydrolysis, and
cleavage of the phosphonucleotide moiety. Additionally, it can liberate free Co which can
perpetuate metal-ion induced oxidant stress. Taken together, this is the first report of generation
of toxic molecular products through the interaction of Cobl with HOCl.
INTRODUCTION
HOCl is a potent oxidant generated by myeloperoxidase (MPO), a neutrophil-derived
heme peroxidase that uses hydrogen peroxide (H2O2) and chloride (Cl-) as co-substrates [171].
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HOCl plays an important role in the innate immune system by oxidatively destroying invading
pathogens and microbes. However, sustained high levels of HOCl may cause host tissue injury
in acute and chronic inflammatory conditions [172]. Activated neutrophils have been reported to
generate around 150−425 μM of HOCl per hour [173, 174]. It is estimated that HOCl levels
reach about 5 mM at sites of inflammation [175].

Indeed, high level of HOCl has been

implicated in development and progression of a number of pathological conditions such as
vasculitis, atherosclerosis, pulmonary fibrosis, diabetic complications, glomerulonephritis,
cancer and even oocyte ageing [1, 176-179]. HOCl also causes protein chlorination [180] and
protein aggregation [100] which have been demonstrated in neurodegenerative disorders such as
in amyloid plaques and Parkinson’s disease [40, 42, 181]. HOCl can react with cyanide (CN-) to
generate an extremely toxic compound, cyanogen chloride (CNCl), which in turn is hydrolyzed
by water to produce hydrogen cyanide (HCN) [182].
CNCl is a volatile and toxic asphyxiant that can affect multiple organs such as the central
nervous, cardiovascular and pulmonary systems[183]. It is an extremely labile molecule and its
toxicity in biological system lies in its ability to release CN- through its reaction with sulfhydryl
compounds such as GSH and protein thiols [184].

The liberated CN- can in turn inhibit

mitochondrial cytochrome oxidase [185] and hence block electron transport, resulting in
decreased oxidative metabolism and oxygen utilization, a fatal process for an organism.
Vitamin B12 is an important water-soluble vitamin which regulates red blood cell and
neural cell activity and displays antioxidant properties [65, 66]. Deficiency of this vitamin has
been associated with megaloblastic anemia and cognitive dysfunction in neurodegenerative
disorders including Parkinson’s and Alzheimer’s disease[71]. Cyanocobalamin (Cobl) is the
most common supplemental form of vitamin B12. Cyanocobalamin at doses of 100 to 1000 µg,
are commonly prescribed for subjects with deficiency of the vitamin in conditions such as
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pernicious anemia [72]. Cobl is produced from hydroxocobalamin, naturally produced by
bacteria, and used in all natural products. In the process of purification and separation of
hydroxocobalamin from bacteria through charcoal (a substance rich with cyanide) columns,
hydroxocobalamin changes to cyanocobalamin form. Cobl’s structure is mainly based on a
corrin ring, which is similar to the porphyrin moiety found in hemoproteins with two pyrrole
rings attached directly to each other and a Co atom residing in the center. Four of the six
coordination sites of Co atom are the pyrrole nitrogen atoms provided by the corrin ring, and a
fifth is a nitrogen of the 5,6- dimethylbenzimidazole group at the lower (or -) axial ligand

Figure 31. Structure of cyanocobalamin.

(Figure 31) [186]. The other nitrogen of the 5, 6-dimethylbenzimidazole is linked to a fivecarbon sugar, which in turn connects to a phosphate group, and then back onto the corrin ring via
one of the seven-amide groups attached to the periphery of the corrin ring.

The sixth

coordination site, known as the center of reactivity, is the upper/-axial ligand occupied by a
cyano group (-CN). These characteristic features make the corrin ring more flexible and less flat
compared to the porphyrin ring.
Recently we have demonstrated that HOCl can oxidatively cleave the heme moiety from
hemoglobin and free heme to release free iron [187, 188]. In this work we extended our
observation to Cobl, a similar corrin macrocyclic compound. Our results for the first time show
that HOCl can mediate destruction of the corrin ring of Cobl, through a mechanism that involves
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disruption of axial coordination of the Co atom and cleavage of the corrin ring. The liberated
CN- reacts with HOCl and generates CNCl.
MATERIAL AND METHODS
Materials
All the materials used were of highest purity grade and used without further purification.
Sodium hypochlorite (NaOCl), pyridine, 1,3 dimethyl barbituric acid, Cobl, L-methionine,
methanol- HPLC grade, were obtained from Sigma Aldrich (St. Louis, MO, USA).
Absorbance Measurements
The absorbance spectra was recorded using a Cary 100 Bio UV–visible
spectrophotometer, at 25oC, pH 7.0. Experiments were performed in a 1-ml phosphate buffer
solution (200 mM, pH 7.4) supplemented with fixed amount of Cobl (11 μM) and increasing
concentration of HOCl (0, 100, 200, 300, 400, 500, 600, 1000 μM). After 2 hours incubation for
reaction completion, methionine (5-fold of the final HOCl concentration) was added to eliminate
excess HOCl and absorbance changes were recorded from 300 to 700 nm.
Rapid Kinetic Measurements
The kinetic measurements of HOCl-mediated Cobl destruction were performed using a
dual syringe stopped-flow instrument obtained from Hi-Tech, Ltd. (Model SF-61).
Measurements were carried out under an aerobic atmosphere at 25C following rapid mixing of
equal volumes of a buffer solution contains fixed amount of Cobl (22 µM) and a buffer solution
containing increasing concentration of HOCl. The time course of the absorbance change was
fitted to a single-exponential (Eq. 1), or a double-exponential (Eq. 2) function as indicated.
Signal-to-noise ratios for all kinetic analyses were improved by averaging at least six to eight
individual traces. In some experiments, the stopped-flow instrument was attached to a rapid
scanning diode array device (Hi-Tech) designed to collect multiple numbers of complete spectra
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(200-800 nm) at specific time ranges. The detector was automatically calibrated relative to a
holmium oxide filter, as it has spectral peaks at 360.8, 418.5, 446.0, 453.4, 460.4, 536.4, and
637.5 nm, which were used by the software to correctly align pixel positions with wavelength.
Y = 1 - e-kt + C

Eq. 1

Y = Ae-k1t + Be-k2t + C

Eq. 2

High Performance Liquid Chromatography (HPLC) analysis
HPLC analyses was carried out using a Shimadzu HPLC system equipped with a SCL10A system controller, with a binary pump solvent delivery (LC-10 AD) module and a SIL10AD auto-injector connected to a SPD-M10A diode array detector (DAD) and a RF-10A XL
fluorescence detector. Alltech 5 µm particle size, 4.6 × 150 mm reverse-phase octadecylsilica
(C18) HPLC column was used. The photodiode array detector was set at 360 nm to monitor the
chromatogram. The column was eluted at a flow rate of 1.0 mL/min with linear gradients of
solvents A and B (A, water; B, methanol). The solvent gradient was as follows: 0 to 15 min, 2085% B; 15 to 20 min, 85% B; then the solvent B composition dropped down to 20% within 21
min and the column was equilibrated at 20% solvent B for 25 min. After treatment of Cobl with
HOCl, 50 μL of the reaction mixture was injected. Each sample was analyzed in triplicate.
Colorimetric detection of CNCl
CNCl was detected colorimetrically using the pyridine-1,3 dimethyl barbituric acid
reagent [189].

In this assay, CNCl reacts with pyridine to form a dialdehyde, Glutacon

dialdehyde, which then reacts with 1,3 dimethyl barbituric acid and condenses to form a violet
colored polymethine dye (Eq. 3). The composition of the pyridine-1, 3, dimethyl barbituric acid
(coloring reagent) was as follows. 1.2 g of 1, 3 dimethyl barbituric acid was dissolved in a
mixture of 12.8 mL of water and 6 mL of pyridine, and then 1.2 mL of HCl was added to the
solution to bring the total volume to 20 mL. 500 µL of coloring reagent was added to 500 µL of
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cyanocobalamin-HOCl reaction mixture and was incubated for 15 minutes at 10○C.

The

absorbance of the resulting violet-colored solution was measured at 587.5 nm against
cyanocobalamin-HOCl reaction mixture (without addition of coloring reagent, but diluted with
equal volume of water) to substract the absorbance due to residual cyanocobalamine. The
amount of CNCl was determined from the extinction coeffcient of 1.03 X105 M-1cm-1 for the
violet colored complex [190].

Eq. 3

Mass spectrometric analysis of Cobl-HOCl reaction mixture
Mass spectrometry (MS) experiments were performed using an Agilent 6410 Triple
Quadrupole mass spectrometer and an Agilent 6210 high resolution TOF instrument coupled
with an Agilent 1200 HPLC system (Agilent Technologies, New Castle, DE), equipped with an
electrospray source. Waters symmetry (Waters Corporation, Milford, MA) C18 column (particle
size 3.5 µm; 2.1 x 100 mm) was used to separate reaction products. Solvent A was H2O with
0.1% formic acid and solvent B was acetonitrile with 0.1% formic acid. The column was
equilibrated with 100% solvent A. The gradient was: 0-45% solvent B over 10 min; 45-95%
solvent B over 10 min; 95% solvent B for 1 min 95-0% solvent B for 1 min; and 100% solvent A
for 13 min. 5 µL of the sample was injected at a flow rate of 0.25 mL/min.

Liquid

chromatography electrospray ionization (LC/ESI) MS in the positive mode was performed by
triple quadrupole MS instrument using the following parameters: spray voltage 4000 V, drying
gas flow 10 L/min, drying gas temperature 3250C, and nebulizer pressure 40 psi. Fragmentor
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voltage was 300 V in MS2 scan mode. Mass range between m/z 300 to 1400 was scanned to
obtain full scan mass spectra. LC/ESI MS with high resolution time of flight (TOF) instrument in
the positive mode was performed using the following parameters: spray voltage 3500 V, drying
gas flow 10 L/min, drying gas temperature 3500C, and nebulizer pressure 40 psi. Fragmentor
voltage was 150 V in full scan mode. Mass range between m/z 100 to 1500 was scanned to
obtain full scan mass spectra. Two reference masses at m/z 121.050873 and m/z 922.009798
were used to obtain accurate mass measurement within 5 ppm.
Solution Preparation
HOCl preparation
HOCl was prepared following a slight modification of a published method [119].
Briefly, a stock solution of HOCl was prepared by adding 1 mL NaOCl solution to 40 mL of 154
mM and the pH was adjusted to around 3 by adding HCl. The concentration of active total
chlorine species in solution expressed as [HOCl]T (where [HOCl]T = [HOCl] + [Cl2] + [Cl3−] +
[OCl−]) in 154 mM NaCl was determined by converting all the active chlorine species to OCl−
by adding a single bolus of 40 µL 5 M NaOH and measuring the concentration of OCl−. The
concentration of OCl− was determined spectrophotometrically at 292 nm (ε = 362 M− 1 cm− 1).
As HOCl is unstable, the stock solution was freshly prepared on a daily basis, stored on ice, and
used within one hour of preparation. For further experimentations, dilutions were made from the
stock solution using 200 mM phosphate buffer pH 7, to give working solutions of lower HOCl
concentration.
Cobl preparation
Cobl stock solution was prepared by dissolving Cobl in distilled water.

The

concentration of Cobl stock solution was determined spectrophotometrically at 361 nm (ε = 27.5
mM− 1 cm− 1).
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RESULTS
Kinetics of reaction of HOCl with Cobl.
We report a kinetic study of the reaction of an isolated, well-characterized Cobl with
HOCl. We first characterized HOCl binding to Cobl and its subsequent effects on its
destruction. Spectrophotometric studies demonstrated that incubation of Cobl with increasing
concentrations of HOCl for 2h caused ligand replacement and Cobl destruction, as judged by a
remarkable shift, decrease, and flattening in the absorbance spectra (Figure 32). Reactions
Figure 32. Spectral changes for concentration
dependence of HOCl-mediated corrin ring
destruction. The dashed line represents spectral traces
of Cobl (11 µM) recorded in phosphate buffer (200
mM, pH 7), at 25°C. Spectral traces (solid lines, from
top to bottom) were recorded after 2 h of incubation of
a fixed amount Cobl with increasing concentration of
HOCl (100, 200, 300, 400, 600 and 1000 µM), at
25°C. Arrows in the panel indicate the direction of
spectral change as a function of increasing
concentration of HOCl. These data are representative
of three independent experiments.
reported here were run in the dark under aerobic condition, at 25°C. The starting trace (dotted
line) is the spectrum of Cobl (11 M) prior to HOCl addition. The prominent absorbance peak
centered at 360 nm with absorbance shoulders at 540 and 550 nm, indicative of intact corrin ring
with CN- as the -axial ligand. Incubation of Cobl with lower concentration (100 M) of HOCl
for 2h caused a distinct shift in UV absorption peak (from 360 to 363 nm), and an additional shift
in the visible absorption region from (550 to 590 nm). This distinct red shift of the absorbance
spectra was indicative of α-axial ligand replacement, as reported earlier [191]. Incubation of
Cobl with higher concentration (>100 M) of HOCl caused decrease and flattening in the
absorbance spectra indicating oxidative destruction of the corrin ring. Traces 1-7 of Figure 32
(solid line from top to bottom) are the end point spectra recorded after incubating identical
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amounts of Cobl with 100, 200, 300, 400, 500, 600, 1000 M of HOCl for 2 hours.
We next utilized stopped-flow kinetic techniques to elucidate the mechanism by which
HOCl mediated ligand replacement and corrin ring destruction. The time courses for the ligand
replacement and the corrin ring destruction monitored at 363 and 590 nm were very similar.
Each had a distinctive lag phase followed by an increase in absorbance which reaches a
maximum intensity in less than 60 s and then decays over a period of approximately 200 min
when a solution of 11 µM of Cobl was rapidly mixed with fixed HOCl concentration of 1000
µM, at 25°C (Figure 33A). The time course for this reaction was fitted to Eq. 2 with values of k1
and k2 of 0.24 and 0.11 s-1, respectively. The lag phase at the start of the reaction can be
attributed to Cobl conformational change or perhaps the ionization of bond 5, 6dimethylbenzimidazole group, which partially limits the rate of axial ligand replacement. These
experiments were conducted with fixed amount of Cobl versus increasing concentration of
HOCl. The conformational change, corresponding to the lag phase, displays similar spectral

Figure 33: HOCl mediates Cobl ligand replacement and corrin destruction. Panel A shows
the stopped-flow trace monitored at 363 nm when a buffer solution containing Cobl (11 µM,
final) was rapidly mixed with an equal volume of buffer solution supplemented with HOCl (1000
µM, final), at 25 °C. The red line represents the theoretical fit generated by the software when
the raw data (blue line) was fitted to a two exponential function (Eq. 2). Panel B contains the
kinetic traces for the reaction monitored at 590 nm, when Cobl (11 µM) was mixed with
increasing concentrations of HOCl (250, 750, 1250 and 1500 µM). These data are representative
of three independent experiments.
characteristics to the native Cobl. The subsequent increase in absorbance that takes place in the
next 60 s can be attributed to the axial ligand (either CN- or 5, 6- dimethylbenzimidazole)
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replacement of the Cobl molecule. Fitting each stopped flow traces obtained as a function of
HOCl concentration to a two-exponential function (Eq. 2) showed that there was a variation in
the observed rate constants.

As shown in Figure 34A, the rate of both phases increased

exponentially when plotted as a function of HOCl concentration. These characteristic slow rates
at low HOCl levels may indicate that axial ligands of Cobl significantly restrict the access of
HOCl to the corrin catalytic site. The parallel exponential increase in both the fast and slow rate
constants may indicate that the ligand replacement rate is limited by the rate of the
conformational change. Figure 33B shows the decrease in absorbance at 590 nm that take place
during the next 200 min of the reaction when increasing concentration of HOCl were rapidly
mixed with a fixed concentration of Cobl (11 µM). This absorbance decrease can be attributed
to Cobl destruction. The variation of the pseudo-first-order rate constant with the final HOCl
concentration was linear, and the plot intersected the axes near the origin (Figure 34B).
Therefore, Cobl destruction mediated by HOCl is essentially irreversible. The second-order rate
constant for the Cobl destruction estimated from the slope is found to be 2 X 10-5 M-1s-1.

Figure 34: Rate constant of -axial ligand replacement and corrin ring destruction of Cobl
as a function of HOCl concentration. The observed rate constants for the formation of Cobl
intermediate upon reacting Cobl with HOCl (panel A) and subsequent Cobl destruction (panel B)
monitored at 363 nm observed in Figure 3 were plotted as a function of HOCl concentration. A
solution containing 11 µM Cobl was rapidly mixed with an equal volume of sodium phosphate
buffer (200 mM, pH 7) supplemented with varying concentration of HOCl at 25 °C. The high
concentration of the phosphate buffer is to keep the pH of the solution unaltered after the
addition of HOCl.
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Liberation of CNCl from Cobl after HOCl treatment
To confirm our results from the spectrophotometric and kinetic studies, that Cobl
interaction with HOCl leads to ligand substitution and corrin ring destruction, we hypothesized
that the liberated CN- will react with excess HOCl in the reaction mixture to form CNCl. Cobl
(110 µM) was treated with different molar ratios of HOCl and the accumulation of CNCl as a
function of increasing molar ratios of HOCl to Cobl was measured using the pyridine-1,3
dimethyl barbituric acid colorimetric assay (see Materials and Methods for details) (Figure 35).
From the plot it can be seen that there is an initial lag phase in the amount of CNCl being formed
(up to 3.5:1 HOCl:Cobl ratio) beyond which the CNCl concentration increases linearly and
plateaus of above 28:1 HOCl:Cobl ratio (Figure 35), suggesting that 28 molecules of HOCl are
required to completely destroy 1 molecule of Cobl and release CNCl.

Figure 35: Cobl destruction mediated by
HOCl causes the liberation of CNCl. Cobl was
treated with increasing molar ratios of
HOCl:Cobl and CNCl generation was assayed
colorimetrically as detailed in the Materials and
Methods section. The data are a representative of
three independent experiments with the error
bars
representing
the
standard
error
measurements.

HPLC analysis of Cobl-HOCl reaction
Figure 36 shows the chromatograms of Cobl treated with increasing molar ratios of
HOCl. Under our experimental condition Cobl eluted around 9 minutes and was identified by its
characteristic spectral peaks at 360, 520 and 545 nm obtained from the diode array detector. As
the HOCl concentration was increased, formation of new products with different retention times
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and spectral properties were seen. As shown in Figure 36, when Cobl was treated with 3.4 times
excess of HOCl there was a significant decrease in the signal for Cobl and concomitant
formation of six new products with spectral characteristics similar to those of incomplete

Figure 36: HPLC analysis of Cobl treated with
increasing concentration of HOCl. Cobl (11 µM) was
treated with different molar ratios of HOCl as indicated in
each panel for two hours and the reaction was stopped by
addition of excess methionine. The reaction mixture was
analyzed by HPLC as detailed in the Materials and
Methods section. The data are a representative of three
independent experiments.

corrinoids as reported earlier [192]. Around 10 min and 13 min we observed two species with
spectral characteristics very similar to that observed from the stopped-flow kinetic experiment.
Therefore, we propose these two compounds might be two stereosiomers of the α-axial ligand
replaced form of the parent Cobl molecule. When HOCl concentration was further increased, all
the incomplete corrinoids disappeared and only the α-axial ligand replaced form persisted.
Finally, at higher concentration (> 60 fold excess of HOCl) there was complete destruction of the
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corrin ring as evidenced from the disappearance of the peaks. From these experiments we
conclude that Cobl interacts with HOCl to undergo ligand replacement in its α-axial position,
which ultimately leads to corrin destruction.
LC-MS analysis of Cobl-HOCl reaction products
LC-MS studies with different molar ratios of HOCl:Cobl reaction mixture was performed
to identify the corrin degradation products. At lower HOCl concentration predominantly intact
Cobl was detected (m/z 1355, Figure 37).

Figure 37: Mass spectrometric detection of
Cobl. The extracted ion chromatogram (A) and
MS spectrum (B) of unreacted Cobl as detected
from the Cobl-HOCl reaction mixture. The
molecular ion was detected in the [M+H]+ form
and had a m/z of 1355.

Another form of Cobl m/z 1354 was detected with the corrin ring and the -axial ligand
intact but where the coordination between the Co atom and the N atom of the 5-6
dimethylbenzimidazole has been disrupted (Figure 38).

Figure 38: Disruption of coordination in Cobl
to form a ‘base-off’ intermediate when reacted
with HOCl. Examination of the MS spectrum
revealed that the [M + H]+ ion had a m/z 1354.
(A) The extracted ion chromatogram. (B) The
MS spectrum of the peak. (C) The assigned
structure of m/z 1354.
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At higher HOCl concentration a chlorinated derivative of Cobl was detected from the
characteristic chlorination isotope pattern, m/z 1389 (Figure 39).

Figure 39: The formation of a chlorinated
derivative of Cobl on reacting with HOCl.
Examination of the MS spectrum revealed that
the [M + H]+ ion had a m/z 1389. (A) The
extracted ion chromatogram. (B) The MS
spectrum of the peak. Note the presence of one
chlorine atom as the ion intensity of the
[M+H+2]+ ion is approximately 40% of [M+H]+,
indicating a chlorine isotope pattern. (C) The
assigned structure of m/z 1389.

The structure of this chlorinated complex reveals a ligand replacement on the α-axial side
of the molecule as indicated from the spectrophotometric and HPLC analyses. The two axial
ligands of the central Co atom are CN- and Cl-, with the phosphonucleotide moiety still intact,
but not coordinated to the Co atom. Further oxidative modification of the m/z 1389 product
leads to the formation of m/z 279 (Figure 40). Ultimately at higher HOCl concentrations a corrin
degradation product was detected which resulted from the oxidative cleavage of the carboncarbon double bond, m/z 579 (Figure 40).

Figure 40: Oxidative modification of the
phosphonucleotide moiety and the corrin
ring of Cobl. Extracted ion chromatogram (A
& B) and MS spectrum (C) of oxidatively
modified phosphonucleotide moiety and corrin
degradation product, detected from the CoblHOCl reaction mixture. The molecular ion was
detected in the [M+H]+ form and had a m/z of
279 and 579. The assigned structures of m/z
279 and 579 are shown in D & E.
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DISCUSSION
Our central finding is that HOCl nonenzymatically mediates Cobl destruction and
subsequent liberation of toxic CNCl. This was independently demonstrated by using direct
spectrophotometric and rapid kinetic measurements as well as colorimetric assay to monitor:
axial ligand replacement and the corrin ring destruction; the degree of oxidation and destruction
of the corrin ring; and the liberation of CNCl.
Our results demonstrate for the first time the significant role of HOCl in disturbing the
stability of Cobl. The UV-visible spectrum of Cobl is extremely sensitive to ligand replacement
of both - and -axial ligands. For example, a significant blue shifted UV-visible spectrum was
produced upon the replacement of the -axial ligand with different substituent (e.g. H2O, CH3,
adenosyl and OH) [193-196] whereas a significant red shifted spectrum resulted upon the
replacement of the dimethylbenzimidazole group attached to -axial with different substituent
(e.g. CN-) [191]. Despite the high affinity of HOCl towards CN- (k on = 1.22x109 M-1s-1, at 25°
C) [182], the present results failed to demonstrate a direct CN- removal prior to the corrin ring
destruction. This conclusion is strongly supported by the high affinity of Co central towards CN
molecule, which prevents the accessibility of HOCl to the -axial position. Instead, HOClmediates the breakage and replacement of the α-axial ligand as judged by the redshifted spectral
displacement when a low concentration of HOCl was added to Cobl (Figure 32). This new
species was predominant at low HOCl concentration and its accumulation was decreased by
increasing HOCl concentration, and completely disappears at higher HOCl concentration (see
Figure 36). The corrin ring destruction seems to account for the complete loss and flattening of
the absorbance spectrum. Changes in the corrin ring geometry upon alteration in oxidation state
of the Co atom or by the replacement of the axial ligands might therefore make the ring more
susceptible to HOCl-mediated oxidation and destruction. Corrin ring opening and/or destruction
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was associated with a significant Co release and liberation of CNCl. The lag phase that was
observed in Figure 35 could be attributed to minimum concentration of HOCl that is required for
ligand replacement prior to corrin destruction. This is consistent with the HPLC analysis (Figure
36) which shows significant accumulation of the chlorinated metabolite at 3.4:1 HOCl:Cobl
ratio.
Insights into mechanisms for HOCl binding to Cobl and novel mode of Cobl destruction
may provide important clues towards understanding the catalytic action of MPO at sites of
inflammation. Using spectral and rapid kinetic measurements, we showed that molecular HOCl
binds to Cobl through a distinct and novel mechanism. Rather than occurring through a simple,
reversible one step mechanism, as is typical for HOCl binding to ferric hemoproteins [187], the
reaction involves several kinetically and spectrophotometrically distinguishable marks. Single
wavelength stopped-flow measurements revealed that the interaction of HOCl with Cobl consists
of at least three elementary steps. The spectral changes at 363 nm over time reveals the presence
of a lag phase with the kinetic tracing over the initial 5s of reaction, followed by an increase in
absorbance in the next 5s, and a decrease in the absorbance over the next few hours. During the
lag phase interval, the coordination environment of the metal center does not change, thus
making reasonable the assumption that this step is associated with weakening and the release of
the -axial ligand. This permits the -axial ligand replacement leading to the formation of a new
hexa-coordinated intermediate.

This process is illustrated by the increase in absorbance

following the lag phase monitored at 363 nm. An identified intermediate with m/z value of 1389
is an example, where the intact nucleotide loop is still attached to the corrin ring but is not
coordinated to the Co atom instead Cl atom is bound to α-axial position. Kinetic traces for the
formation of the chlorinated intermediate as a function of HOCl concentration were best fitted to
a two exponential function (Figue 33A). As shown in Figue 34A, the dependence of the pseudo-
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first-order rate constants of both phases on the concentration of HOCl are noticeably curved
indicating that the reaction order of this substitution reaction in Cobl is higher than 1. In fact,
there are second order in the HOCl concentration and the reactions follow the rate expression
(kobs = k1[HOCl]2) with second order rate constants of the first and second phase of 1 X 10-7 µM2 -1

s and 3 X 10-7 µM-2s-1, respectively. On the basis of the similar trends and close proximity of

the value of the rate constants for the first and second steps, we concluded that the chlorinated
intermediate is generated through two consecutive steps as shown in Figure 41.

Figure 41:
Kinetic model
depicting the reaction between
Cobl and HOCl leading to
ligand replacement and corrin
ring destruction.

Our data clearly showed that α-axial ligand replacement initiates corrin ring destruction
and the release and fragmentation of the 5,6 dimethylbenzimidazole group. The oxidation of
Cobl by a slight excess of HOCl was accompanied by a remarkable change from red color to
colorless. The disappearance of Cobl spectra could be due to the loss of hyperconjugation in the
molecule, Co atom release, and/or Cobl fragmentation. The rate constant of Cobl destruction
obtained by fitting the decrease in absorbance monitored at 363 nm to a one exponential function
is relatively slow with a positive slope (2 X 10-5 M-1s-1) obtained when HOCl concentration was
plotted against observed rate constant. The zero y-intercept confirms the irreversible nature of
the reaction. The severity of Cobl destruction as assessed by the number and chain lengths of the
various oxidative metabolites and subsequent buildup of CNCl is HOCl concentration dependent.
These findings extend our recent work that showed the ability of HOCl to mediate the
destruction of metal-ion derivatives of tetrapyrrole macrocyclic rings and their significant role in
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HOCl scavenging.
A proposed chemical mechanism that describes the modification and fragmentation of
Cobl is shown in Figure 42 A & B. In this model, HOCl first oxidized the tertiary alcohol group
in the furanose molecule of the 5,6 dimethylbenzimidazole ligand to a ketone. This reaction
proceeds through the attack of the ClO3- anion generated from OCl- (3OCl-  ClO3- + 2Cl-)
[197]. The H atom of the tertiary alcohol group forms a hydrogen bond with the adjacent O- of
the phosphate moiety to form a stable 6 membered ring. The reaction mechanism is analogous to
oxidation of alcohols by Dess–Martin periodinane reagent [198, 199]. However, the higher
stability of this six membered ring favors the oxidation of the tertiray alcohol as opposed to the
primary alcohol of the furanose molecule. In this reaction, ClO3- is added onto the O atom on the
phosphate group which occurs by donation of the lone pair of the O atom to the Cl atom of ClO3.
In the next step, a proton is exchanged with the solvent and following intamolecular electron
rearrangement (as shown in Figure 42), the alcohol group is oxidized to a ketone.

Figure 42A: Proposed mechanim
of ligand replacement and corrin
ring cleavage.
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Simultaneously with this oxidation there is a breakage or weakening of the coordination
between Co and the N of the 5,6 dimethylbenzimidazole, leading to a ‘base-off’ conformation of
the molecule. This molecule with a molecular weight of 1353 was identified in LC-MS as m/z
1354 in the electrospray positive mode. The m/z 1354 compound then undergoes a ligand
replacement where a Cl-, generated from OCl- (as mentioned above) binds to α-axial side of the
structure. This chlorinated derivative is identified as m/z 1389 in LC-MS, with a distinct
chlorine isotope pattern. Subsequent to the ligand replacement reaction there is a cleavage of the
phosphate group (through a simple acid hydrolysis as shown in Figure 42A) of the 5,6
dimethylbenzimidazole moiety (identified as m/z 359) leading to the removal of

this

phosphonucleotide from the Cobl molecule. Additionally, there was oxidative cleavage of the
corrin ring, as described previously [187, 188] which leads to the formation of di-corrinic
derivative identified as m/z 579. The phosphonucleotide moiety that was cleaved from the Cobl
molecule underwent further oxidative modification. Initially the hydroxide group (liberated from
homolytic cleavge of the HOCl molecule) attacked the H atom of the five membered ring (as
shown in the scheme) and eliminate the H as a water molecule. This led to the formation of a
benzyl radical, from which the electron on the carbon atom attacked the bond between the
esterifed O and the carbon chain. In the next step through further attack of another molecule of
HOCl and subsequent intramolecular electron rearrangement, the phosphate group is released
with the formation of an tertiary carbonyl group on the five membered carbon ring. The
dephosphorylated moiety undergoes further oxidative modifications to form a demethylated
epoxide compound, m/z 279 through a mechanism as shown in Figure 42B. Based on previously
published mechanisms of HOCl’s reaction with carbon-carbon double bonds, any of the three
double bonds in the six membered ring could form an epoxide. Also, any of the two methyl
groups can potentally get demethylated by HOCl as shown in our mechanism.

Since the
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structure of the m/z 279 is only based on mass analysis, the exact location of the epoxide and the
demethylation remains to be clarified. Thus, Cobl is a potent scavenger of HOCl as evident from
our finding that one molecule of Cobl has the potential capacity to scavenge multiple molecules
of HOCl. The cobalt moiety of hydroxocobalamin avidly binds to intracellular cyanide (with
greater affinity than cytochrome oxidase) forming cyanocobalamin. This molecule is stable,
with few side effects, and is readily excreted in the urine. Therefore, hydroxocobalamin has
been used to treat cyanide poisoning in clinical settings [200, 201].

Figure 42B: Proposed
mechanism
of
dephosphorylation and
demethylation.

However, acute or chronic inflammation can potentially lead to excess HOCl in
inflammatory microenvironment where the antioxidant defenses are overwhelmed.

In this

scenario, the interaction of HOCl with Cobl can lead to localized toxic effects. The mechanisms
through which toxicity of HOCl interaction with Cobl is mainly due to: the release of free Co
that may initiate an immunologic reaction in hypoxic and inflammatory states [202]; and the
release of CNCl/CN- that can lead to the inhibition of mitochondrial cytochrome oxidase [185].
A recent study has demonstrated that reactive oxygen species like superoxide can be scavenged
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by intracellular Cobl when antioxidant defenses are overwhelmed [203]. Free Co might reduce
molecular oxygen to cobalt bound oxygen radical adduct having strong oxidant properties [64].
It may also take part in Fenton-like reactions and produce hydroxyl radical (OH) in the presence
of superoxide dismutase (SOD) and hydrogen peroxide (H2O2) at sites of inflammation [64].
Cobalt has also been demonstrated to initiate reactive oxygen species in cancer cells and brain
tissues and affect proliferation and cause DNA damage[64]. Cyanogen chloride is a colorless-topale yellow liquid that turns into a gas near room temperature. This reagent is a highly toxic
chemical asphyxiant affecting mitochondrial respiration. Thus, supplementation with a HOCl
scavenger may provide a beneficiary effect through prevention of the formation of CNCl.
Indeed, previous studies by Matthews have shown that treatment of HL60 cells (cells expressing
MPO) by Cobl led to cytotoxicity, which could be prevented by adding methionine, a potent
scavenger of HOCl, to the medium [204].
Multiple lines of evidence suggest that MPO may play a role in atherogenesis, lung
disorders and various types of cancer. For example, immunohistochemical and biochemical
analyses showed the enzyme and its oxidation products to be localized within human
atherosclerotic lesions [205] and ovarian cancer cells [206]. HOCl–mediated Cobl destruction
may also exert indirect cardiovascular effects through its ability to disrupt the conversion of
homocysteine /folic acid to methionine. Thus, enhanced levels of HOCl may lead to increased
serum levels of homocysteine, a risk factor for cardiovascular disease [207]. HOCl-mediated
Cobl destruction may also disturb the conversion of methylmalonic acid to succinyl-CoA [67],
an input to the citric acid cycle [208, 209]. Previously, we have shown that MPO may serve as a
source of free iron under oxidative stress when both NO and O2•− are elevated [117]. It has also
been shown that iron accumulates in atherosclerotic lesions in a catalytically active form. More
recently, we have shown that HOCl can promote heme destruction in free heme, hemoproteins,
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and red blood cells leading to iron release and protein aggregation [187]. Our work, thus,
provide some exciting evidence to support the relationship between elevated levels of free metals
and elevated activity of MPO. The role of MPO in the destruction of tetrapyrrole macrocyclic
rings and the release of free metals may provide an additional pathway for the involvement of
MPO in lipoprotein oxidation in vivo [210].
Therefore, inhibiting MPO and/or eliminating its final products may play a beneficiary
role in biological systems in reducing the metal release mediated by HOCl. Related studies from
our lab have shown that MPO can be inhibited at three different points: 1) through heme
reduction that causes collapse or narrowing in heme pocket geometry that prevents the access of
the substrate to the catalytic site of the enzyme (e.g. ascorbate) [211]; 2) switching the MPO
catalytic cycle from peroxidation to catalase-like activity (e.g. melatonin, tryptophan, tryptophan
analogs) [146-149, 212]; or 3) direct scavenging of HOCl (e.g. lycopene) [133].
Vitamin B12 is essential for neural function and a significant portion of elderly population
is deficient in this water-soluble vitamin [73]. Our results indicate that this vitamin displays a
beneficial effect in scavenging HOCl, or a harmful effect in chronic inflammatory states by
destroying Cobl and generating free Co, CNCl and CN. It appears that in a system with optimal
concentrations of vitamin B12, the scavenging property is well utilized, but in antioxidant
deficient states, the effect of HOCl dominates and free cobalt generated in the process may add
to the vicious cycle of generation of more oxidative stress.
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CHAPTER 4
Lycopene as a potent scavenger of hypochlorous acid
ABSTRACT
We next examined the role of lycopene in scavenging HOCl. Lycopene, a carotenoid
found in tomatoes, is a proven anti-oxidant that may lower the risk of certain disorders including
heart disease and cancer. HOCl is an oxidant linked to tissue oxidation in cardiovascular disease
and other inflammatory disorders through its ability to modify proteins, deoxyribonucleic acid,
ribonucleic acid and lipids. Here we show that lycopene can function as a potent scavenger of
HOCl at a wide range of concentrations that span various pathophysiological and supplemental
ranges. The oxidation of lycopene by HOCl was accompanied by a marked change in color,
from red to colorless, of the lycopene solution suggesting lycopene degradation. HPLC and LCMS analysis showed that the exposure of lycopene to increasing concentrations of HOCl gave a
range of metabolites resulting from oxidative cleavage of one or more C=C. The degree of
degradation of lycopene (as assessed by the number and chain lengths of the different oxidative
metabolites of lycopene) depends mainly on the ratio between HOCl to lycopene, suggesting that
multiple molecules of HOCl are consumed per molecule of lycopene. Collectively, this work
demonstrates a direct link between lycopene and HOCl scavenging, and may assist in elucidating
the mechanism of the protective function exerted by lycopene.
INTRODUCTION
Lycopene, the red pigment of tomato, is a tetraterpene assembled from eight isoprene
units composed entirely of carbon and hydrogen, containing 11 conjugated and 2 nonconjugated
carbon–carbon double bonds (C = C) (Figure 43). It is one of the most interesting unsaturated
carotenoids with well-known health benefits [213, 214]. The lycopene concentration in human
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Figure 43. Structure of all trans-lycopene. The number represents the carbon number in
hydrocarbon chain.

serum tends to be higher than those of all other carotenoids pigments [214]. Increasing evidence
suggests that lycopene could be involved in protection against chronic disorders such as
cardiovascular disease, prostate cancer, and respiratory and digestive epithelial cancers [215218]. Lycopene exerts potent anti-inflammatory effects through its action as an antioxidant and
free radical scavenger, which may reduce cellular damage [219, 220]. It also plays an important
role in protecting cell membranes from lipid peroxidation by neutralizing hydroxyl radicals and
may bind to DNA, promoting further protection beyond antioxidant activity. Additionally,
lycopene may stimulate antioxidative enzymes such as superoxide dismutase, glutathione
peroxidase, and glutathione reductase [221], as well as inhibiting hydrogen peroxide (H2O2)induced lipid peroxidation and lipoprotein modification [222].

The mechanism by which

lycopene exerts these antioxidant properties in vivo has not yet been elucidated.
Lycopene metabolites generated through lycopene oxidation may have activities different
from those of lycopene or can display completely new and independent biological functions [88].
Indeed, studies from several laboratories have demonstrated potential beneficial effects of
lycopene specifically in response to oxidants. These beneficial functions include enhanced
cellular gap junction communication, induction of phase II enzymes through activation of the
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antioxidant response element transcription system, suppression of insulin-like growth factor-1stimulated cell proliferation by induction of insulin-like growth factor binding protein,
antiangiogenesis, inhibition of cell proliferation, and induction of apoptosis [88, 223].
HOCl and its conjugate base (OCl−) are potent oxidants that function as powerful
antimicrobial agents [224].

However, the properties of HOCl that make it such a potent

antimicrobial agent may also endanger the host, as it can damage the host tissue by the same
mechanism used to destroy invading pathogens [107]. HOCl is generated enzymatically by
MPO, a neutrophil-derived heme peroxidase, which uses H2O2 produced during respiratory burst
to catalyze the two-electron oxidation of chloride (Cl−). HOCl is implicated as a contributing
factor in a number of pathological conditions such as but not limited to inflammatory diseases,
atherosclerosis, respiratory distress, acute vasculitis, rheumatoid arthritis, glomerulonephritis,
and cancer [110, 111, 225-227]. Recently, we showed that HOCl plays an important role in
accelerating oocyte aging through a mechanism that involves oocyte fragmentation and
degradation [228]. Various types of biological molecules react with HOCl. For example,
NADH and NH groups of pyrimidine nucleotides are chlorinated by a HOCl-induced reaction.
HOCl causes extensive denaturation of double-stranded DNA [229, 230]. HOCl can convert
tyrosine residues in a protein to form 3-chlorotyrosine [231]. In lipids the major sites of attack
by HOCl are the double bonds of unsaturated fatty acids and cholesterol, leading to either
chlorohydrin formation [231] or peroxidation [232, 233]. In addition to being a potent oxidant
itself, HOCl can react with other compounds to produce other reactive oxidant species (ROS)
and free radicals. For example, HOCl can react with superoxide (O2−•) to generate hydroxyl
radical (•OH) [35, 36]. In alkaline solution hypochlorite, the conjugate base of HOCl, reacts with
H2O2 to yield singlet oxygen species [37].

Importantly, these ROS and free radicals
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subsequently generated from HOCl may cause further cellular damage.
MPO and its downstream final products have recently been used as markers for many
chronic disorders. Consequently, inhibition of MPO and/or eliminating its end product, HOCl, is
a topic of great interest in several laboratories. More recently, we have shown that melatonin,
tryptophan, and tryptophan analogues display the potential capacity to reversibly inhibit MPO
through the accumulation of MPO Compound II (MPO–Fe(IV)=O), an inactive MPO
intermediate [74, 146, 149]. The aim of this work is to highlight the potential role of lycopene as
a pathway of HOCl scavenging and to identify the HOCl-mediated oxidative products of
lycopene and their cleavage mechanism. Identification of a potent scavenger of HOCl from
dietary supplements may provide novel avenues for preventing initiation, progression, and
development of inflammation-related pathological states.
MATERIALS AND METHODS
Materials
All the materials used were of highest purity grade and used without further purification.
Lycopene was obtained from Toronto Research Chemicals Inc. (ON, Canada).

Sodium

hypochlorite (NaOCl), tetrahydrofuran (THF), ammonium acetate (CH3COONH3), taurine, and
5, 5–Dithiobis (2-nitro-benzoic acid) were obtained from Sigma Aldrich (St. Louis, MO, USA).
HPLC grade methanol, acetonitrile (CH3CN), isopropanol and chloroform were obtained from
Acros (Belgium).
Spectral analysis
Optical spectra were recorded on a Cary 100-Bio UV-visible spectrophotometer at 23°C.
Lycopene was prepared as 4 mM stock solution dissolved in chloroform and stored at -80 °C
until further use. Care was taken not to expose lycopene solution to light, either during stock
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solution preparation or experimentation.

To measure the effect of HOCl on lycopene

destruction, 12.5 μL aliquots of the lycopene stock solution were removed and diluted to 500 µl
CHCl3 in Pyrex test-tubes, and the lycopene solutions then received equal volume of aqueous
solution (500 μL) containing increasing concentration of HOCl (0-3750 μM). The solution
mixtures were vortexed continuously for 2 min in the dark and the aqueous layer was removed.
50 μL from the organic phase was diluted to 1 ml in CHCl3 and the absorbance spectra were
scanned form 200 to 700 nm.
High Performance Liquid Chromatography (HPLC) analysis
HPLC analyses was carried out using a Shimadzu HPLC system equipped with a SCL10A system controller, with a binary pump solvent delivery (LC-10 AD) module and a SIL10AD auto-injector connected to a SPD-M10A diode array detector (DAD). Alltech 5 µm
particle size, 4.6 × 150 mm reverse-phase octadecylsilica (C18) HPLC column was used. The
column was kept at 27°C. The photodiode array detector was set at 450 nm to obtain the
chromatogram. The gradient system used was a slight modification of a previously published
method [234]. After oxidation with HOCl, the chloroform layer was evaporated under a stream
of nitrogen and then the dried sample was re-suspended in the injection solvent (25 μL CHCl3
and 975 μL CH3CN) solution, and 50 μL were injected. The column was eluted at a flow rate of
1.0 mL/min with linear gradients of solvents A and B (A, CH3CN: THF: 1% CH3COONH3 in
H2O = 50:20:30, v/v/v; B, CH3CN: THF: 1% CH3COONH3 in H2O = 50:44:6, v/v/v). The
solvent gradient used were, A-70 %, B-30% at start, then a linear gradient increase of B to 70 %
in 70 min, then a steeper gradient to increase B to 100 % in 1 min and hold at 100 % B for 10
min. At the end of the run the system was equilibrated with 100 % solvent A. Under these
conditions, lycopene eluted at around 46 min and was detected from the characteristic spectral
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signal from the Diode Array Detector. Each sample was analyzed in triplicate.
Mass spectrometric analysis
Mass spectrometry (MS) experiments were performed using an Agilent 6410 Triple
Quadrapole mass spectrometer coupled with an Agilent 1200 HPLC system (Agilent
Technologies, New Castle, DE), equipped with a multimode source. Alltech Prevail C18 column
(particle size 5 µm; 4.6 x 150 mm; Nicholasville, KY) was used to separate reaction products.
Solvent A was methanol and solvent B was isopropanol. The column was equilibrated with 80%
solvent A and 20% solvent B. The gradient was: 20-50% solvent B over 12 min; 50% solvent B
for 2 min; 50-20% solvent B for 1 min; and 80% solvent A for 15 min. 2 L of the reaction
mixture was injected at a flow rate of 1 mL/min. Liquid chromatography atmospheric pressure
chemical ionization (LC/APCI) MS in the positive and negative modes were performed using the
following parameters: spray voltage 2500 V, drying gas flow 5 L/min, drying gas temperature
3500C, vaporizer temperature 1500C, and nebulizer pressure 20 psi. Flow injection analysis
(FIA) was used to optimize the fragmentor voltage. Optimal fragmentor voltage for lycopene
was 130 V in MS2 scan mode. Mass range between m/z 100 and m/z 700 was scanned to obtain
full scan mass spectra.
Solution preparation
HOCl preparation
HOCl was prepared following a slight modification of a published method [34]. Briefly,
a stock solution of HOCl was prepared by adding 7.5 ml NaOCl solution to 10 ml potassium
phosphate (KH2PO4) solution (100 mM). The concentration of HOCl in this stock solution was
determined by the taurine chloramine assay [235]. As HOCl is unstable, the stock solution was
freshly prepared on a daily basis, stored on ice, and used within one hour of preparation. For
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further experimentations, dilutions were made from the stock solution using 100 mM KH2PO4, to
give working solutions of lower HOCl concentration.
RESULTS
HOCl promotes lycopene oxidation
Lycopene, a member of the carotenoid pigment family, possesses a characteristic red
color and like all carotenoids, has the ability to absorb light in the 400–500 nm region of the
visible spectrum. We initially studied the reaction of HOCl with lycopene to understand the role
of lycopene in HOCl scavenging and to isolate and identify lycopene cleavage products.
Reactions were carried out at 25°C in chloroformic solution. From our initial experiments we
observed the disappearance of lycopene color to determine whether HOCl promotes its
oxidation. The oxidation of lycopene by a slight excess of HOCl was accompanied by a marked
change from red color to colorless (Figure 44, inset). The color disappeared rapidly, and after 2
min a complete loss of the red color of lycopene occurred. Figure 44 compares the absorbance
spectra of lycopene exposed to increasing concentrations of HOCl with that of untreated
Figure 44. Lycopene spectral changes as a
function of HOCl concentration. Absorbance
spectra of lycopene alone (top most spectra) and
after reaction with 50, 125, 250, 500, 750, 1250,
1875, 2500 and 3750 µM HOCl, respectively (from
top to bottom). The arrows show the direction of
the absorbance decrease as a function of increasing
HOCl ratio. The inset shows the color change of
lycopene solution (50 µM) when reacted with 3750
µM of HOCl.

lycopene. The visible spectrum of lycopene displayed characteristic peaks centered at 460, 486,
and 520 nm in chloroform. Exposure of a fixed amount of lycopene to increasing concentrations
of HOCl caused lycopene exhaustion, as indicated by the flattening, shift, and disappearance of
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its characteristic absorbance peaks. Lycopene is an unsaturated hydrocarbon with 13 C = C, of
which 11 double bonds are conjugated and the characteristic UV–visible spectra of lycopene are
due to these hyperconjugated double bonds in the molecule (Figure 43). The disappearance of
lycopene spectra could be due to the loss of hyperconjugation in the molecule and/or lycopene
fragmentation.
HPLC analysis of lycopene oxidation products
As HOCl is thought to oxidize carotenoids, we examined whether these spectral
transformations that are apparent from our UV–visible spectral analysis may represent the
oxidation and subsequent fragmentation of lycopene by HOCl. HPLC analysis was performed
(as mentioned under Materials and methods) to study the reaction products after oxidation of
lycopene with HOCl. We incubated a fixed amount of lycopene (50 µM) with increasing HOCl
concentrations (250, 500, 625 µM).

When lycopene was reacted with HOCl there was a

progressive reduction in the lycopene signal (as a function of HOCl concentration) along with
the formation of new peaks eluting at earlier time. Figure 45A shows the chromatograms for
control and the various reaction mixtures at 450 nm. In our method lycopene eluted at 47 min
and was identified by its characteristic spectra observed from the photodiode array detector.
Calculating the area under the curve for lycopene revealed that in a sample treated with 250 µM
HOCl 12% of the lycopene was remaining, whereas in 500 µM HOCl 0.5% of lycopene was
remaining. Complete loss of the lycopene peak was observed in 625 µM HOCl (Figure 45B). T
he fact that there is residual lycopene remaining at 500 µM HOCl proves that one molecule of
lycopene is capable of scavenging multiple molecules of HOCl. The appearance of newer earlier
eluting peaks in the chromatograms could be due to the formation of new compounds with
shorter chain lengths and subsequently lower hydrophobicity.
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Figure 45A. HPLC analysis of the HOCl induced
lycopene oxidation products. The figure shows the
chromatograms obtained at 450 nm, when lycopene (50
µM) was reacted with different concentrations of HOCl.
Panel A: 0 µM, B: 250 µM, C: 500 µM and D: 625 µM
HOCl respectively. The chromatograms are the
representative set from three independent experiments.

Figure 45B. Percent of lycopene remaining
after reaction with different concentrations
of HOCl. 50 µM of lycopene was reacted with
different concentrations of HOCl (0, 250, 500,
625 µM respectively) and after HPLC analysis
(for details see Materials and Methods
section) the area under the curve for lycopene
signal was integrated. The above result is the
mean of three independent experiments and
the error bars represent the Standard Error of
Measurement.

LC/APCI/MS analysis of lycopene oxidation products
LC/APCI/MS was utilized to elucidate whether HOCl-mediated reaction products of
lycopene were indeed due to oxidation and fragmentation of the lycopene molecule. To optimize
the MS parameters 100 pmol of lycopene was first analyzed by FIA at various fragmentor
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voltages in APCI positive and negative ionization modes. The optimal fragmentor voltage for
lycopene was determined to be 130 V in MS2 scan mode. Several solvent systems were
evaluated to obtain the maximal ion intensity of the MS detector. Ammonium acetate and
tetrahydrofuran suppressed ion intensity. Therefore, we chose isopropanol because this solvent
has the same polarity as tetrahydrofuran and does not significantly suppress ionization. A
methanol and isopropanol gradient as described under Materials and methods gave the best ion
intensity (data not shown).
Figure 46. Liquid Chromatography
atmospheric
pressure
chemical
ionization mass spectrometry (positive
mode) of reaction of lycopene with
HOCl (lycopene:oxidant ratio 1:5). The
reaction mixture was separated by
reverse phase HPLC and subjected to
APCI/MS as described in Materials and
Methods. The major reaction product
produced an intense peak at 2.86 min.
Examination of the MS spectrum
revealed that the [M + H]+ ion had a m/z
393. The extracted ion chromatogram
(Panel A) and the MS spectrum of this
peak (Panel B) are depicted.
The predominant species of lycopene metabolite in the chloroformic solution with
lycopene:HOCl of 1:5 was eluted at 2.86 min and identified as m/z 393 in the APCI positive
mode. The extracted ion chromatogram for m/z 393 and the mass spectrum of this compound are
depicted in Figures 46A & B, respectively. The second major peak was observed at 1.75 min
and identified as m/z 349. This compound contains two carbonyl groups and represents double
oxidative modifications (Figure 47 and Table 3).
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Figure
47.
Liquid
Chromatography
atmospheric pressure chemical ionization
mass spectrometry (positive mode) of reaction
of lycopene with HOCl (lycopene:oxidant
ratio 1:5). The reaction mixture was separated
by reverse phase HPLC and subjected to
APCI/MS as described in Methods. The second
major reaction product produced an intense peak
at 1.75 min. Examination of the MS spectrum
revealed that the [M + H]+ ion had a m/z 349.
The extracted ion chromatogram (Panel A) and
the MS spectrum of this peak (Panel B) are
depicted.
Table 3. Structures of HOCl oxidized lycopene metabolites tentatively identified by LC-MS
studies.

Incubation of lycopene at 1:10 and 1:12.5 ratios gave a range of metabolites. In the

98
sample with a ratio of 1:10 (lycopene to HOCl) a series of long-chain compounds was obtained
with m/z values of 301, 393, 413, 437, 441, 469, and 475 and elution times of 2.05, 2.86, 2.69,
1.85, 2.96, 3.18, and 1.78 min, respectively. In contrast, after the incubation of lycopene with a
higher concentration of HOCl/OCl− (1:15 and 1:20) all the lycopene was consumed, and traces of
m/z 301 were still detectable. In addition, the chloroformic solution with a ratio of 1:15 showed
the formation of two new metabolites with elution times of 2.26 and 2.38 min with m/z values of
329 and 421, respectively, whereas the solution of a ratio of 1:20 led to the generation of three
new metabolites: (a) m/z 443, elution time 1.86 min; (b) m/z 443, elution time 2.14 min; and
(c)m/z 449, elution time 2.03 min. The extracted ion chromatogram of m/z 443 is depicted in
Figure 48A showing the two elution times for this mass indicating the presence of two distinct
compounds. Examination of the mass spectrum (Figure 48B) of the first compound reveals the
Figure 48. Novel reaction products of
lycopene with HOCl (lycopene:oxidant ratio
1:20). The reaction mixture was separated by
reverse phase HPLC and subjected to APCI/MS
as described in Methods. Two new metabolites
were detected at retention times 1.86 min and
2.14 min. Examination of the MS spectrum
revealed that the [M + H]+ ion had a m/z 443.
The extracted ion chromatogram is shown in
Panel A. The MS spectrum of the peak at 1.86
min (Panel B) and 2.14 min (Panel C) are
depicted. Note presence of one chlorine atom as
the ion intensity of [M + H + 2]+ ion is
approximately 40% of [M + H]+ indicating
chlorine isotope pattern in Panel B. In contrast,
the isotopic pattern of m/z 443 from the second
peak has no intense [M + H + 2]+ ion (Panel C)
indicating that this product is not chlorinated.
presence of one chlorine atom as the ion intensity of the [M + H + 2]+ ion is approximately 40%
of [M + H]+, indicating a chlorine isotope pattern. In contrast, the isotopic pattern of m/z 443
from the second peak has no intense [M + H + 2]+ ion (Figure 48C), indicating that this product

99
is not chlorinated. In the negative ion mode, peaks were observed for m/z values of 255, 281,
283, 409, 437, and 473 with elution times of 2.12, 2.07, 2.40, 2.50, 2.80, and 4.12 min,
respectively.
The majority of the products were tentatively identified by detecting the corresponding
molecular weight and comparing the proposed structures with the previously identified products
and/or owing to the chemical reactivity of HOCl with carotenoids [236]. Identification of the
eluted reaction products identified the presence of three types of lycopene oxidation products.
The first group contains lycopene metabolites resulting from single oxidative cleavage. These
metabolites contain on one end and acid and/or an aldehyde group and on the other end the Ψend group of lycopene and are called apo-lycopenal and apo-lycopenoic acids. In the positive
APCI mode, the m/z 393 (Figure 46) and m/z 443 (Figure 48) are probably produced by single
oxidative cleavage.
The second group contains lycopene metabolites resulting from a double oxidative
cleavage. This category of lycopene metabolites contains two acid end groups and is called apocarotendials, because their structure could have been obtained from any carotenoids and not only
from lycopene. The m/z 349 (Figure 47) represents such a compound.
The third group contains other compounds resulting from further chlorination of group 2
and is called chloro-apo-carotendials. The m/z 443 (Figure 48B; retention time 1.86 min)
represents a chlorinated lycopene metabolite.
DISCUSSION
Increased levels of HOCl, a potent oxidant, are typically observed in the plasma and
tissues of individuals with inflammatory diseases [6]. Yet, a functional deficiency of taurine, a
potent HOCl scavenger, is a defining feature of diabetes, obesity, depression, hypertension, gout,
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kidney failure, and autism, among other conditions [123, 237, 238]. Previous epidemiological
evidence has suggested that the intake of lycopene is associated with a reduced risk for many
chronic disorders, including prostate cancer and heart disease [238].

Although most

investigators have attributed the potential protective role of lycopene in the prevention of chronic
diseases to its antioxidant function [239], the exact mechanism by which lycopene exerts these
antioxidant effects has not been fully elucidated. Using a combination of direct UV–visible,
HPLC, and LC/APCI/MS, we have shown that increasing concentrations of HOCl can alter the
availability of lycopene through a mechanism that involves lycopene oxidation and
fragmentation. Exposure of lycopene to saturating amounts of HOCl caused a distinct bleaching
of color, suggesting lycopene destruction. HPLC and LC–MS analysis showed that exposure of
lycopene to increasing concentrations of HOCl gave a range of metabolites resulting from the
oxidative cleavage of one or more C=C. HOCl may directly mediate the destruction of lycopene
by nonselective cleavage at any double bond position in a nonenzymatic manner.

HOCl-

mediated lycopene oxidation was rapid in chloroformic solution, and a total of 13 cleavage
products have been identified based on their mass signals through the treatment of lycopene
solution with a range of HOCl (1:5 to 1:20 molar ratio). The degree of degradation of lycopene
(as assessed by the number and chain lengths of the various oxidative metabolites of lycopene)
depends mainly on the ratio of HOCl to lycopene, suggesting that multiple molecules of HOCl
are consumed per molecule of lycopene. Thus, HOCl interaction with lycopene may serve as a
potential mechanism for modulating its availability, thereby influencing the regulation of local
inflammatory and infectious events in vivo.
These cleavage products can be classified into three major categories according to the
degree of oxidation and their cleavage position within the lycopene molecule: the first group
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contains lycopene metabolites resulting from single oxidative cleavage.

These metabolites

contain on one end and aldehyde and/or an acid group and on the other end the Ψ-end group of
lycopene and were called apo-lycopenal and apo-lycopenoic acids. Indeed, two apo-lycopenal
and two apo-lycopenoic acids were obtained and tentatively identified based on the m/z value.
Apo-lycopenal isolated fragments showed that the double bond 5–6 (or 5′–6′) was affected,
whereas apo-lycopenoic acid showed that the double bonds 13–14 (or 13′–14′), 15–15′, and 9–10
(or 9′–10′) was affected by the cleavage. All the apo-lycopenoic acid fragments (acycloretinoic
acid, apo-14′-lycopenoic acid, and apo-10′-lycopenoic acid) were identified at both low (1:5) and
high (1:20) lycopene to HOCl ratio. Apo-lycopenal fragments (apo-6′-lycopenal) were identified
at only higher lycopene to HOCl ratio (Table 3). The second group resulted from the oxidation
and modification of both end groups of lycopene that could occur at position 1–2 (or 1′–2′) or at
any other position to produce lycopene metabolites with two acids, two aldehydes, or a
combination of both acid and aldehyde on the two end groups and was called apo-carotendials,
because their structure could have been obtained from any carotenoids and not only from
lycopene. In the case of apo-carotendials, the double bond 1–2 (or 1′–2′) on one side and the
double bond 7–8 (or 7′–8′) on the other side were shown to be affected, whereas the
corresponding acids showed that the double bonds 7–8 (or 7′–8′), 11–12 (or 11′–12′), and 5–6 (or
5′–6′) were affected by the cleavage. In addition, among the various products isolated, three
fragments were oxidatively modified at both ends of lycopene's hyperconjugated chain. These
three products were crocetin semialdehyde, crocetin, and apo-5′, 6′-carotendial (Table 3). The
third group contains other compounds resulting from further chlorination of lycopene
metabolites, called chloro-apo-carotendials.

These include m/z 443, which is a chlorinated

lycopene fragment: 2-hydroxy-3-chloro-4,6,8,10,12,14,16,18-docosoctene 1,22-diol-6,11,15,19-
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tetramethyl. Thus, taken together, the results of our studies suggest that the HOCl-mediated
cleavage reaction of lycopene and the degree of oxidation could occur non selectively at any
position of the lycopene double bonds independent of HOCl concentration. The formation of
long chains was not detected at higher ratio of lycopene to HOCl (e.g., 1:30, data not shown),
suggesting that the detected fragments are further oxidized to shorter chain lengths upon
increasing the HOCl concentration.
In the case of potassium permanganate-mediated generation of apo-carotendials, CarisVeyrat et al. [240] have shown that only the double bonds 5–6 (or 5′–6′), 7–8 (or 7′–8′), 9–10 (or
9′–10′), and 11–12 (or 11′–12′) were affected by the cleavage. But they did not detect apocarotendials/ones resulting from cleavages of double bonds closer to the center of the molecule
(15–15′ C = C) [240]. No cleavage was detected on the double bond that is the farthest from the
center of the molecule, i.e., the 1–2 double bond, which is not conjugated and is trisubstituted.
The authors attributed this behavior to the nonreactivity of these positions to the oxidation with
potassium permanganate [240]. No products resulting from a double oxidative cleavage (apocarotendial) were detected upon exposure of lycopene to the oxidative catalytic species transdioxoruthenium(VI) tetraphenylporphyrin Ru(O)2 over a period of 96 h [240]. Instead (Z)isomers, compounds with a molecular weight of m/z 553 = [Mlycopene + 16 + H]+, which were
called lycopene monoxides, and cleavage compounds assigned to apo-lycopenals were detected
[240]. Almost all the apo-lycopenals/ones that were obtained by oxidation of lycopene with
potassium permanganate were detected, except the short-chain apo-5-lycopenone and apo-7lycopenal [240]. Thus, our results may suggest that HOCl behaves as a stronger oxidant with a
higher oxidation potential than permanganate and other oxidants for lycopene destruction.
Many of the metabolites in groups 1 and 2 have been reported, as their metabolic
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pathways were investigated extensively, whereas other cleavage products and their functions are
either not yet fully explained or not mentioned before in the literature. For example, earlier in
vitro studies by Ben-Aziz et al. have shown that apo-6′- and apo-8′-lycopene were obtained by
oxidation of lycopene with potassium permanganate [241]. Cross-sequential studies by Ukai et
al. described a protocol for the reaction that gave apo-6′-lycopenal as the main product after 44 h,
whereas 50% of lycopene remained intact [242].

Caris-Veyrat et al. later optimized the

experimental conditions by modifying the solvent mixture and the phase transfer catalyst to
completely oxidize lycopene and obtained mono-oxidative cleavage compounds as major
products [240].

After the complete disappearance of lycopene, they detected eight apo-

lycopenals giving a range of products from the longest apo-6′-lycopenal to the shortest one
detected, apo-5-lycopenone; three apo-lycopenones; and six apo-carotendials [243].

Using

HPLC analysis with UV–visible detection Kim et al. have tentatively identified mono cleavage
compounds of lycopene [244]. Exposure of lycopene to atmospheric oxygen and perfusion of
ozone led to the tentative identification of (E,E,E)-4-methyl-8-oxo-2,4,6-nonatrienal [243]. Kim
et al. isolated and identified a cleavage product of lycopene from an autoxidation mixture of
lycopene products [244].
Previous studies have also shown that lycopene undergoes oxidative degradation in vivo
[244]. Some of the lycopene cleavage products identified in this work (Table 3) have been
shown to participate in biological effects in animal models and cell culture system. Indeed,
several of the lycopene metabolites have been found in human milk and serum [245]. Consistent
with our current finding, these studies have concluded that lycopene can nonselectively be
cleaved at any double-bond position in a nonenzymatic manner when organisms are subjected to
oxidative stress [234, 240, 243, 246]. Because several of the HOCl-mediated lycopene cleavage
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products of different chain lengths assigned to groups 1 and 2 (Table 3) have been identified and
shown to be associated with reduced risk of certain cancers [247-250], we believe that our work
could be biologically relevant. Indeed, it has been thought that lycopene metabolites may induce
changes in the expression of relevant genes and serve as anticancer agents [251]. Related studies
by Nara et al. have shown that a mixture of oxidation products of lycopene induced apoptosis in
HL-60 cells after incubation for 24 h at 37◦C [252]. Kotake-Nara et al. have shown that
acycloretinoic acid, the centrally cleaved metabolite of lycopene, reduces cell viability by
inducing apoptosis in human prostate cancer cells [253]. Aust et al. have shown that 2,7,11trimethyltetradecahexaene-1,14-dial, generated by lycopene degradation, enhances cell-to-cell
communication through gap junctions in rat liver epithelial WB-F344 cells [254]. In addition,
apo-10′-lycopenoic acid was also found to be a lycopene metabolite in ferret lung tissue [255].
In parallel, several other lycopene metabolites with different functional groups have previously
been reported, for example, 5,6-dihydroxy-5′,6′-dihydrolycopene and 2,6-cyclolycopene-1,5-diol
A and B have been found in extracts of human serum/plasma [245] and [256].
Identifying similarities and differences in the interactions between HOCl and various
oxidants yields valuable mechanistic insights into the potential biochemical and functional
significance of HOCl–lycopene interactions both in vitro and in vivo. On the basis of the present
results, previous published studies of the interactions of HOCl with carotenoids, and the
exposure of lycopene to various oxidants (e.g., permanganates and metalloporphyrins), we have
generated a stepwise scheme that shows possible pathways for the generation of various
lycopene cleavage products after exposure to increasing concentrations of HOCl (Figure 49). In
this reaction, lycopene interacts with the HOCl molecule, and the chloride atom of HOCl acts
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Figure 49. Proposed chemical mechanism showing the stepwise oxidation of lycopene by
HOCl.
as an electrophile and the electron-rich olefin initially acts as the nucleophile. When the Cl atom
adds across the double bond, it does so in such a manner that a pseudo-secondary carbo-cation is
formed, transforming to a more stable chloronium ion. Addition of the hydroxide proceeds by
obeying the regioselectivity of nucleophilic chloronium ion ring opening. The semihalohydrin
then undergoes an epoxide-ring-forming reaction via an intramolecular SN2-type reaction in
which a chlorine atom is displaced. Reaction of the epoxide with a second molecule of HOCl
(deprotonated by Cl−) causes cleavage of the terminal carbon–carbon bond and the generation of
an aldehyde (which is one carbon shorter than the parent epoxide from which it was formed).
Further oxidation of the aldehyde by a third molecule of HOCl leads to the formation of
carboxylic acid. Thus, it is evident that one molecule of lycopene (which has 13 C=C) has the
potential to scavenge multiple molecules of HOCl.
The degree of reproducibility and similarity of the isolates increased progressively when
the LC–MS analyses were carried out immediately after the extraction of the cleavage products
in chloroformic solutions and subsequently as dry powders. The delay of 20–45 h in LC–MS
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analysis caused a noticeable decrease in the chlorinated compounds (group 3), indicating that the
chlorinated molecules are relatively unstable and may decay to nonchlorinated species such as
aldehydes and carboxylic acids. The metabolites in group 3 and their metabolic pathways have
not been previously reported. The excessive HOCl generated under inflammatory conditions
when phagocytes are activated and MPO is released may play a harmful role because of its
ability to react eagerly with a variety of biological molecules and its ability to chlorinate as well
as oxidize biomolecules [257]. Indeed, there is substantial evidence that MPO and HOCl play a
role in atherosclerosis, diabetes, and asthma, and HOCl-mediated tissue injury has also been
found to result in an increase in inflammatory disorders as determined by increased levels of free
and protein-bound chlorotyrosine and α-chloro fatty aldehydes (reviewed in [178, 210]).
The generation of a series of chlorohydrins of cholesterol [6-β-chlorocholestane-(3β,5α)diol, 5-α-chlorocholestane-(3β,6β)-diol, and 6-α-chlorocholestane-(3β,5β)-diol] has been
observed after exposure to HOCl, as well as a dichlorinated product, 5,6-dichlorocholestane-3βol [30, 258]. In addition to electrophilic addition, HOCl can utilize N-halogenation reactions at
amines in the head groups of phosphatidylethanolamines and phosphatidylserines, yielding
corresponding chloramines [259, 260].

These intermediate products are initial short-lived

molecules and tend to decay to a more stable nonchlorinated species such as aldehydes. HOCl
reacts very rapidly with the sulfur-containing side chains of methionine and cysteine residues
and, at a slightly lower rate constant, with amines and other nitrogen-containing residues [261,
262]. The ability of lycopene to scavenge HOCl formed during inflammatory situations is more
likely to prevent proteins and unsaturated phospholipids from MPO- and HOCl-induced damage.
Thus reduced lycopene availability and/or increased consumption as assessed by the degree of its
fragmentation and modification may reflect the basic mechanism of increasing the risk of
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diseases induced by MPO and HOCl.
In summary, inhibition of MPO or removing its downstream final product, HOCl, is an
attractive target for preventing HOCl-mediated tissue injury and progression of inflammatory
diseases. In this study we advance the current knowledge of lycopene antioxidant properties and
show for the first time that lycopene may serve as a potent scavenger of HOCl. The interplay
between lycopene and HOCl may have a broad implication in the function of inflammatory
biological systems throughout the body. Further evaluation is necessary to assess whether
lycopene could represent an interventional approach to minimize the deleterious effects
associated with inflammation.
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CONCLUSIONS
For the first time, this work has established a mechanistic link between high HOCl and
free iron. Results from Chapter 1 unambiguously demonstrate that elevated levels of HOCl can
cause destruction of the heme moiety from Hb in a cell free system as well as from isolated
RBCs to liberate iron, while the tetrapyrrole metal center does not seem to play a role in the
pattern of ring cleavage (see Chapter 2).
In addition to generating free iron, HOCl mediated heme destruction will lead to an
irreversible alteration of the normal Hb function of transporting oxygen from the lungs to the
tissue. Our results show that interaction of HOCl with oxy-Hb leads to the oxidation of heme
iron to its ferric form, leading to the formation of met-Hb. Met-Hb is incapable of binding
oxygen and accumulation of met-Hb or met hemoglobinemia leads to tissue hypoxia [263].
Accumulation of met-Hb and depletion of the ferrous Hb pool will also inhibit the nitrite
reductase activity of Hb, which will have an adverse effect on the compensatory vasodilation
process that occurs during increased oxygen demand and/or hypoxia.
HOCl mediated heme degradation products have a sensitive, intrinsic fluorescent that
could easily be utilized as an analytical tool to study heme degradation in biological systems.
Current methods to measure free iron levels is cumbersome and most analytical techniques
measures total iron content in a sample without giving any information about the speciation (free
or bound) of the iron. Therefore, these fluorescent heme degradation products could be used as
an index for free iron levels.
From our understanding of the chemistry of the process of HOCl mediated heme
degradation, it seems likely that this process would be operative not only for Hb but also for
other hemoproteins. Indeed, ongoing studies in our laboratory have shown HOCl can act in a
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similar manner to destroy lactoperoxidase and also have an inhibitory feedback effect on MPO
itself, generating iron. These findings have enormous physiological significance. Availability of
iron is essential for bacterial growth [63].

Our results indicate if HOCl is not promptly

scavenged/consumed at the site of generation, it can possibly change the MPO/H2O2/Cl- system
from bactericidal to conducive to bacterial growth. An important translational aspect of these
studies is that the knowledge of the mechanism of how HOCl causes Hb heme destruction could
be utilized to devise possible therapeutic strategies of prevention. Ongoing studies in our
laboratory have shown that melatonin can significantly inhibit HOCl mediated heme destruction
from Hb. This can have a far-reaching impact for developing possible therapeutic strategies in
conditions such as atherosclerosis and sickle cell disease, where HOCl mediated free iron
accumulation is observed. Currently, we are studying the effect of melatonin in altering free iron
release from sickle cell Hb and sickle cell RBCs.
In chapter 3 we extend the findings of chapter 2 and show that HOCl can mediate
destruction of Cobl, Co containing tetrapyrrole macrocyclic ring.

Extensive analytical

characterization of the reaction showed that HOCl generated cyanogen chloride (CNCl) through
a mechanism that initially involves α-axial ligand replacement. CNCl is a toxic blood agent that
can release CN− by reacting with sulfhydryl compounds [184]. This is the first report of
generation of CNCl through the interaction of Cobl with HOCl.
Despite the significant role of HOCl in a number of debilitating pathological conditions,
no effective HOCl scavenger has yet been developed. To this effect, lycopene was shown to be
an effective scavenger for HOCl, with one molecule of lycopene having the potential of
scavenging 39 molecules of HOCl (Chapter 4). Several novel bioactive cleavage products were
generated when lycopene reacted with HOCl. In this study, we also detected a chlorinated
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cleavage product.

This is the first report of the formation of a chlorinated species from

carotenoids. Additionally, these lipophilic lycopene metabolites have the potential to be used an
index/biomarker for assessing the extent of HOCl mediated damage to the lipid soluble
compartments in the cell.
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Hypochlorous acid (HOCl) is a potent oxidant generated by the hemoprotein
myeloperoxidase. Although HOCl plays an important role in the innate immune response,
sustained high levels of HOCl has been implicated to play a harmful role.

In several

pathological conditions such as atherosclerosis, endometriosis and sickle cell disease where
HOCl is elevated there are reports of significant free iron accumulation. Free iron is toxic since
it can lead to the generation of other secondary free radicals such as hydroxyl radical by Fenton
reaction. The exact source and mechanism by which the free iron is generated is not clearly
understood. This work establishes a mechanistic link between high HOCl and elevated free iron.
Our results show that HOCl can mediate heme destruction from hemoglobin and red blood cells
to liberate free iron. HOCl was also shown to aggregate the protein moiety of hemoglobin. To
understand the chemistry of the process to a greater extent, the reaction products obtained when
hematin and protoporphyrin was reacted with HOCl, was compared to those obtained when
purified hemoglobin or red blood cells were treated with HOCl. Detailed HPLC and mass
spectrometric analysis of the reaction products revealed that the presence of the metal center
does not play any role in the pattern of cleavage of the tetrapyrrole ring. Subsequent studies
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showed that treatment of cyanocobalamin with HOCl, also led to generation of proinflammatory
reaction products such as cyanogens chloride. Given the role of HOCl in generating free iron
and cyanogen chloride it would be beneficial to scavenge HOCl. In this respect, we report that
lycopene a common dietary carotenoid displays excellent HOCl scavenging property. Owing to
the extensive hyperconjugation in its structure, one molecule of lycopene theoretically has the
capability to scavenge 39 molecules of HOCl. Currently the only known biomarker of HOCl is
3-chlorotyrosine and 3, 5-dichloro tyrosine, both of these two are hydrophilic. But the reactivity
of HOCl extends to the lipophilic compartments as well. Lycopene and its oxidation products
are lipophilic in nature. Therefore lycopene oxidative fragments have the potential to be used as
a biomarker for HOCl mediated damage to the lipophilic compartments in the cell.
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